



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00101100.6


Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE, 06/04/01
LA HAYE, LE





**Eur päisch s
Patentamt**

**European
Patent Office**

**Office eur péen
des brevets**

**Blatt 2 d r Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.: 00101100.6
Demande n°:

Anmeldetag:
Date of filing: 20/01/00
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Cedars-Sinai Medical Center
Los Angeles, CA 90048
UNITED STATES OF AMERICA

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Transdifferentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat: US
State:
Pays:

Tag: 20/01/99
Date:
Date:

Aktenzeichen: USA 234332
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

C12N5/10, G01N33/50, A61K48/00, A61P25/00

Am Anmeldetag benannte Vertragsstaaten:

Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

**TRANSDIFFERENTIATION OF TRANSFECTED EPIDERMAL BASAL CELLS
INTO NEURAL PROGENITOR CELLS, NEURONAL CELLS AND/OR GLIAL
CELLS**

EPO - Munich
24

20. Jan. 2000

BACKGROUND OF THE INVENTION

5 Throughout the application various publications are referenced in parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in the application in order to more fully describe the state of the art to which this invention pertains.

1. FIELD OF THE INVENTION

10 The present invention is related to the medical arts, particularly to the field of neural tissue regeneration.

2. DISCUSSION OF THE RELATED ART

15 The human nervous system comprises highly diverse cell types that make specific interconnections with one another. The nervous system includes the peripheral nerves and the central nervous system. The central nervous system includes the brain, cranial nerves, and spinal cord. Once damaged, the central nervous system of the adult has limited potential for structural self-repair. The general inability of the adult to generate new neurons (excitable cells specialized for the transmission of electrical signals from one part of the body to another) typically prevents the regeneration of neural tissues. This limitation has hindered the development of therapies for neurological injury, for example from stroke or physical trauma,
20 or for degenerative diseases, such as Huntington disease, Alzheimer disease, and Parkinsonism. The moderate success of fetal tissue transplantation therapy for Parkinsonism suggest that cell replacement therapy can be a valuable treatment for neurological injury and degeneration.

25 Thus, there is a long felt need in the biomedical field for a method of generating neurons for use in the treatment of various neurological traumas, diseases, disorders, or maladies via the direct transfer of neuronal cells in a cell replacement therapy approach.

30 A gene therapy approach, on the other hand, is required to treat other types of nervous system disorders. Because the brain is protected by a blood-brain barrier that effectively blocks the flow of large molecules into the brain, peripheral injection of growth factor drugs, or other potentially therapeutic gene products, is ineffective. Thus, a major challenge facing

the biotechnology industry is to find an efficient mechanism for delivering gene therapy products, directly to the brain, so as to treat neurological disorders on the molecular level. In this regard, a renewable source of human neural cells could serve as a vehicle to deliver gene therapy products to the brain and the rest of the central nervous system.

5 Until recently, the only source of donor material for these promising therapies was fetal tissue. However, the use of fetal tissue presents significant ethical and technical problems, including the limited availability of fetal tissue, the possible immuno-rejection of donor material by the recipient, and the risk of disease transmission by donor material.

10 Several attempts have been made to address the shortage of donor material by culturing neural progenitor cells, or neural stem cells. For example, Boss *et. al* taught a method for isolation and proliferation of neural progenitor cells directed to growth, storage, production and implantation of the proliferated donor cells. (Boss *et. al*, *Proliferated Neuron Progenitor Cell Product and Process*, U.S. Patent No. 5,411,883). Anderson *et. al* taught a method for isolation and clonal propagation of donor mammalian neural crest stem cells
15 capable of self renewal and differentiation into neural or glial cells. (Anderson *et. al*, *Mammalian Neural Crest Stem Cells*, U.S. Patent No. 5,589,376). Johe taught a method for isolation, propagation and directed differentiation of stem cells from the central nervous system of embryonic and adult mammalian donors. (Johe, *Isolation Propagation and Directed Differentiation of Stem Cells from Embryonic and Adult Central Nervous System of Mammals*, U.S. Patent No. 5,753,506).
20

 Neural progenitor cells normally develop from embryonic ectodermal tissue. Bone Morphogenetic Protein (BMP) is a family of repressors that prevents ectoderm from developing into its default state of neural tissue and induces the development instead of epidermal tissue. (Y. Tanabe & T.M. Jessell, *Diversity and Pattern in the Developing Spinal Cord*, Science 274:1115 [1996]; Y. Sasai, *Identifying the missing links: genes that connect neuronal induction and primary neurogenesis in vertebrate embryos*, Neuron 21:455-58 [1998]; Y. Furuta *et al.*, *Bone morphogenetic proteins (BMPs) as regulators of dorsal forebrain development*, Development 124(11):2203-2212 [1997]). BMP 2 and BMP 4 induce epidermal differentiation. (E. Pera *et al.*, *Ectodermal Patterning in the Avian Embryo: Epidermis Versus Neural Plate*, Development 126:63 [1999]).
25
30

 BMP's can also induce cartilage formation. Hattersley *et al.* showed that adding BMP 13 to a cell line derived from mouse limb buds leads to the formation of chondroblast-like cells and taught a method for using BMP 13 to induce articular cartilage formation at the site of congenital or trauma induced damage and for using BMP 9 to maintain cartilage.

(Hattersley *et al.*, *Cartilage Induction by Bone Morphogenetic Proteins*, U.S. Patent No. 5,902,785).

BMP signal transduction appears to be mediated by *msx1*, which is an immediate early response gene involved in epidermal induction and inhibition of neuronal differentiation. When Suzuki *et al.* injected BMP RNA into *Xenopus* embryos, they detected *msx1* RNA production; when they injected *msx1* RNA, the embryos lost neuronal structures such as eyes. (Suzuki *et al.*, *Xenopus msx1 Mediates Epidermal Induction and Neural Inhibition by BMP4*, *Development* 124:3037 [1997]). When *msx1* was added directly to dissociated ectodermal cells, epidermal development was up-regulated and neural development was down-regulated.

Similarly in humans, BMP growth factors induce expression of the homeodomain transcription factor MSX1 in ectodermal cells. Once MSX1 is expressed, induction of the neuronal determination genes is simultaneously suppressed and neuronal differentiation is inhibited.

BMP seems to down-regulate neural development through at least two mechanisms: proteolysis of MASH1 protein and inhibition of Zic3 production. Exposure of neural progenitor cells to BMP triggered a rapid loss of MASH1 protein, a transcription factor that is homologous to the *Drosophila* Achaete-Scute Complex (ASH1) and required for the production of olfactory receptor neurons. (Shou *et al.*, *BMPs Inhibit Neurogenesis by a Mechanism Involving Degradation of a Transcription Factor*, *Nat. Neurosci.* 2: 339 [1999]). Micro-injection of the dominant negative form of the BMP receptor, an inhibitor of BMP, into *Xenopus* embryos induced production of Zic3, a protein that augments neural development. (Nakata *et al.*, *Xenopus Zic3, a Primary Regulator Both in Neural and Neural Crest Development*, *Proc. Natl. Acad. Sci.* 94: 11980 [1997]).

Antagonists of BMP signal transduction activity include fetuin glycoprotein, also known as $\alpha 2$ -HS glycoprotein in humans, and the DAN family of BMP antagonists, such as noggin, chordin, follistatin, and gremlin. (R. Merino *et al.*, *The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb*, *Development* 126(23):5515-22 [1999]; D. Sela-Donnenfeld and C. Kalcheim, *Regulation of the onset of neural crest migration by coordinated activity of BMP4 and noggin in the dorsal neural tube*, *Development* 126(21):4749-62 [1999]). For example, Demetriou *et al.* showed that fetuin blocks osteogenesis, a function promoted by BMP, in a culture of rat bone marrow cells and that a fetuin derived peptide binds BMP 2. (M. Demetriou *et al.*, *Fetuin/ Alpha2-HS Glycoprotein is a Transforming Growth Factor-Beta Type II Receptor Mimic and Cytokine Antagonist*, *J. Biol. Chem.* 271:12755-61 [1996]). During embryonic and early postnatal

development, Fetuin was shown to be present in a sub-population of cells in the retinal ganglion cell layer, the neuroblastic layer, and portions of the developing cerebellum. (Kitchener *et al.*, *Fetuin in Neurons of the Retina and Cerebellum During Fetal and Postnatal Development of the Rat*, Int. J. Dev. Neurosci. 17: 21 [1999]).

5 Fetuin has been used as an additive in serum free media. Ham *et al.* taught the use of fetuin as an additive in serum free media for the growth of normal human muscle satellite cells directed at transplantation to the muscles of patients afflicted with muscle degenerative diseases. (Ham *et al.*, *Media for Normal Human Muscle Satellite Cells*, U.S. Patent No. 5,143,842; Ham *et al.*, *Media for Normal Human Muscle Satellite Cells*, U.S. Patent No. 10 5,324,656). Baker taught the use of fetuin as an additive in a defined serum free media that is capable of growing a wide range of cell suspensions and monolayers. (Baker, *Serum-Free Cell Culture Medium and Process for Making Same*, U.S. Patent No. 4,560,655).

Other factors beside BMP appear to be involved in regulating neural differentiation. Ishibashi *et al.* demonstrated that persistent expression of Hairy and Enhancer of Split 15 Homolog-1 (HES1) severely perturbs neuronal and glial differentiation. They infected the lateral ventricles of the brains of embryonic mice with a retrovirus that produced HES1. This led to failed migration and differentiation in the developing cells that were infected. (Ishibashi *et al.*, *Persistent Expression of Helix-Loop-Helix Factor HES-1 Prevents Mammalian Neural Differentiation in the Central Nervous System*, The EMBO Journal 13: 20 1799 [1994]). Ishibashi *et al.* also disrupted the HES1 gene in mice and observed earlier than usual neurogenesis. They concluded that HES1 controls the timing of neurogenesis. (Ishibashi *et al.*, *Targeted Disruption of Mammalian Hairy and Enhancer of Split Homolog-1 (HES-1) Leads to Up-Regulation of Neural Helix-Loop-Helix Factors, Premature Neurogenesis, and Severe Neural Tube Defects*, Genes & Development 9: 3136 [1995]). In 25 addition retinoids, such as retinoic acid, may play a role in inducing the differentiation of some neural cell populations. (e.g., Y. Renoncourt *et al.*, *Neurons derived in vitro from ES cells express homeoproteins characteristic of motoneurons and interneurons*, Mechanisms of Development 79:185-97 [1998]).

Thus, the differentiation of neuronal tissue involves the interaction of numerous 30 positive and negative regulatory molecules. In response to developmental signals within each cell and its surrounding microenvironment, every neuronal population expresses a specific set of neural markers, neurotransmitters, and receptors. As neural progenitor cells differentiate into other neuronal cell types in response to physiological signals in the microenvironment, the set that is expressed will be different. (E.g., see D.L. Stemple and

N.K. Mahanthappa, *Neural stem cells are blasting off*, Neuron 18:1-4 [1997]; Y. Renoncourt *et al.*, *Neurons derived in vitro from ES cells express homeoproteins characteristic of motoneurons and interneurons*, Mechanisms of Development 79:185-97 [1998]; A.J. Kalyani *et al.*, *Spinal cord neuronal precursors generate multiple neuronal phenotypes in culture*, J. Neurosci. 18(19):7856-68 [1998]). Each neuronal cell type is characterized by several criteria including morphology (e.g., long processes or neurites), expression of a set of neural-specific markers (e.g., neurofilament M, neural-specific tubulin, neural-specific enolase, microtubule associated protein 2, and others), synthesis of neurotransmitters (e.g., dopamine or expression of tyrosine hydroxylase, the key enzyme in dopamine synthesis), and membrane excitability.

One of the central principles of modern neurobiology is that after differentiation each of the major projection neurons, if not all neuronal cell types, requires for its survival specific cytokines, i.e., neurotrophic or nerve growth factors, to reach their target neuronal cells. Neuropathies in many diseases may be caused by, or involve lack of, such nerve growth factors. These nerve growth factors represent the next generation of preventative and therapeutic drugs for nervous system disorders. Most of the growth factors known so far in the nervous system were discovered by their effects on peripheral nerves and these most likely represent a very minor fraction of existing growth factors in the brain. Search for growth factors from the brain has been difficult mainly because particular neuronal cell types are difficult to isolate from the brain and maintain in defined culture conditions.

Due to this limitation, drug discovery by traditional pharmacology directed to the central nervous system has been performed using whole brain homogenate and animals. These studies mostly produced analogs of neurotransmitters with broad actions and side effects. But as more and more neurotransmitter receptors and signal transducing proteins have been identified from the brain, it is becoming clear that the dogma of one neurotransmitter activating one receptor is an over-simplification. Most receptor complexes in neurons are composed of protein subunits encoded by several genes and each gene synthesizes many different variations of the protein. These variations result in a wide range of possible receptor combinations, and not a single receptor that can interact with a neurotransmitter. Consequently, a range of signal output may be produced by a single neurotransmitter action. The specific signal effected by a neurotransmitter on a neuron, then, depends on which receptor complex is produced by the cell. Thus, cellular diversity must parallel the molecular diversity and constitute a major structural element underlying the complexity of brain function, and a source of diverse neuronal cell types that can be cultured for drug screening purposes is needed.

Therefore, there remains a need in the field of neurological research and applied neurobiology for a renewable non-fetal source of neural progenitor cells and cells having characteristics specifically associated with neuronal or glial cell types, for use in research, cell therapy, or gene therapy. Importantly, the use of such cells could eliminate a need for fetal human tissue in therapeutic approaches aimed at restoring neurological function by intracerebral transplantation of nervous system cells. These and other benefits the present invention provides as described herein.

SUMMARY OF THE INVENTION

The present invention relates to a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor cell, a neuronal cell, or a glial cell. The method involves culturing a proliferating epidermal basal cell population comprising one or more epidermal basal cell(s) derived from the skin of a mammalian subject. These epidermal basal cell(s) are transfected, in vitro, with one or more eukaryotic expression vector(s) that contain at least one cDNA encoding a human neurogenic transcription factor, or homologous non-human counterpart, or active fragment(s) thereof, such as NeuroD1, NeuroD2, ASH1, Zic1, Zic3, or MyT1, such that at least one of the neurogenic transcription factor(s) is expressed in the cell. The transfected cell(s) are grown in an in vitro growth medium in which is present at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and/or human HES1 gene, or homologous non-human counterpart of either of these, thereby suppressing at least one negative regulator of neuronal differentiation; and the cell(s) are, optionally, further grown with a retinoid and at least one neurotrophin, such as BDNF, CNTF, PDGF, NGF, NT-3, NT-4, or sonic hedgehog, or a cytokine comprising IL-6. By the inventive method the cell(s) is transdifferentiated into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell.

The present invention also relates to a transdifferentiated cell(s) of epidermal origin. The inventive transdifferentiated cell is a cell of epidermal basal cell origin that displays one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell. The physiological and/or immunological feature can be, but is not limited to, expression of one or more marker(s) specific to a neural progenitor, neuronal, or glial cell, by which the transdifferentiated cell is recognized as a neural progenitor, neuronal or neuron-like cell, or a glial or glial-like cell.

The present invention also relates to cell cultures derived from the inventive

transdifferentiated cell(s).

The present invention is also directed to a method of delivering locally secretable regulatory factors using the inventive transdifferentiated cells, which are genetically modified, before or after their transdifferentiation, with an expression vector comprising a DNA
5 encoding a preselected secretable regulatory factor or a biochemical precursor thereof, or a DNA encoding an enzyme that catalyzes the synthesis of either of these. The genetically modified, transdifferentiated cells are implanted into a mammalian subject, and the implanted cells secrete the locally secretable regulatory factor.

The present invention also relates to method of using the inventive transdifferentiated
10 cell(s) to identify a novel nerve growth factor or potential chemotherapeutic agent. The methods involve transdifferentiating a population of proliferating epidermal basal cells into neuronal progenitor cells, neuronal cells, or glial cells; culturing the transdifferentiated cells; exposing the cultured cells, in vitro, to a potential nerve growth factor (i.e., neurotrophin or neurotrophic factor) and/or potential chemotherapeutic agent; and detecting the presence or
15 absence of an effect of the potential nerve growth factor and/or potential chemotherapeutic agent on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of the cells. The presence of an effect altering cell survival, a morphological or electrophysiological characteristic and/or a molecular biological property of the cells indicates the activity of the potential nerve growth factor and/or potential
20 chemotherapeutic agent.

The present invention also relates to a method of using the inventive transdifferentiated cell(s) to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin. In the method the epidermal basal cells are derived from a human subject having a particular nervous system disorder of genetic origin. The cells are transdifferentiated
25 in accordance with the inventive method. The transdifferentiated cells are cultured and exposed, in vitro, to a potential chemotherapeutic agent. The method involves detecting the presence or absence of an effect of the potential chemotherapeutic agent on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of said cells. An effect altering cell survival, a morphological or electrophysiological
30 characteristic and/or a molecular biological property of the cells indicates the activity of the chemotherapeutic agent.

The present invention is also related to a kit for transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell. The kit is useful for practicing the

inventive methods.

The present invention is directed to methods of converting, or transdifferentiating, epidermal cells into different types of neural cells having numerous uses in the field of applied neurobiology. In particular, the newly created neurons of the invention can be used in both cell therapies and gene therapies aimed at alleviating neurological disorders and diseases. Further, the invention obviates the need for human fetal tissue as a renewable source of neurons to be used in various medical and research applications.

These and other advantages and features of the present invention will be described more fully in a detailed description of the preferred embodiments which follows.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Transdifferentiation of epidermal basal cells into neuronal cells. Dedifferentiated epidermal basal cells were transfected with NeuroD1+Zic1+MyT1 and simultaneously treated with antisense oligonucleotides corresponding to a portion of MSX1 and HES transcription factors. (A) epidermal basal cells, (B) dedifferentiated epidermal basal cells, (C) newly created neurons, 25% of cells are Neurofilament M immunoreactive 5 days after transfection and treatment with BDNF and all-trans retinoic acid.

15

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

An awareness of the difficulties currently associated with neuronal cell or gene therapy approaches, as these pertain to the use of alternative sources of neuronal cells, especially those used for autologous transplantation, has led to the present invention. The present invention provides methods to convert, or transdifferentiate, epidermal cells into different types of neuronal cells that can be used for intracerebral transplantation. Importantly, the present invention also allows for genetic manipulation of the newly created neurons.

20

A significant aspect of the present invention is that it permits the use of a patient's own cells to develop different types of neuronal cells that can be transplanted after *in vitro* growth and transdifferentiation. Thus, this technology eliminates the problems associated with transplantation of non-host cells, such as, immunological rejection and the risk of transmitting disease.

25

The present invention can be used to generate neurons from an individual patient, thus making autologous transplantations possible as a treatment modality for many neurological conditions including neurotrauma, stroke, neurodegenerative diseases such as Parkinson's

30

disease, Huntington disease, Alzheimer's diseases. Thus, the invention provides for neurological therapies to treat the disease or trauma of interest.

To summarize, this technology provides a plentiful source of neurons for clinical treatments which require transplantation of neurons 1) to compensate for a loss of host
5 neurons, or 2) as vehicles to deliver genetically-based drugs. Further, the invention provides a novel neurological tool for use in basic research and drug screening.

The theoretical molecular basis of the present invention exploits the orchestrated actions in neuronal development of numerous molecular processes including epigenetic signaling and activation of specific transcription factor systems. During development,
10 ectodermal cells develop into neuronal tissue or epidermis, depending on the signals they receive from the surrounding cells. At this early developmental stage, activation of various members of the bone morphogenetic protein family (BMP) of growth factors results in epidermal differentiation, while blocking their action results in neuronal differentiation. (See Tanabe and Jessel, 1996, for a review.) This differentiation pathway is due to the action of
15 BMP growth factors which induce expression of the homeodomain transcription factor MSX1 in ectodermal cells. Once MSX1 is expressed, induction of the neuronal determination genes is simultaneously suppressed and neuronal differentiation is inhibited. (Suzuki et al., 1997).

Alternatively, retinoic acid and Sonic Hedgehog (Shh) signaling are responsible for the induction of expression of several neuronal determination and differentiation genes whose
20 activity is essential for neuronal differentiation. (See Tanabe and Jessel, 1996, for a review.) In particular, data demonstrate that over-expression of several neurogenic basic Helix-Loop-Helix (bHLH) and Zinc-finger transcription factors results in conversion of non-determined ectoderm into neuronal tissue. Additionally, forced expression of bHLH transcription factors, NeuroD1, NeuroD2 (Lee, J.E., Hollenberg, S.M., Snider, L., Turner,
25 D.L., Lipnick, N. and Weintraub, H. (1995). Conversion of *Xenopus* ectoderm into neurons by neuroD, a basic helix-loop-helix protein. *Science* 268, 836-844; McCormick, M.B., Tamimi, R.M., Snider, L., Asakura, A., Bergstrom, D. and Tapscott, S.J. (1996). NeuroD2 and NeuroD3: distinct expression patterns and transcriptional activation potentials within the neuroD gene family. *Mol. Cell. Biol.* 16, 5792-5800), or neurogenin 1 (Ma, Q., Kintner, C.
30 and Anderson, D.J. (1996). Identification of neurogenin, a vertebrate neuronal determination gene. *Cell* 87, 43-52; McCormick et al., 1996), or Zinc-finger transcription factors MyT1 (Bellefroid, E.J., Bourguignon, C., Hollemann, T., Ma, Q., Anderson, D.J., Kintner, C. and Pieler, T. 1996. X-MyT1, a *Xenopus* C2HC-type zinc finger protein with a regulatory function in neuronal differentiation. *Cell* 87, 1191-1202.) or Zic3 (Nakata et al., 1997) results

in induction of additional neurogenic transcription factors and initiation of neuronal differentiation of amphibian ectodermal cells.

Moreover, at the level of gene regulation, the effect of neurogenic bHLH transcription factors is antagonized by the HES family of transcription factors which are known to suppress transcription. Over-expression of HES1 protein in developing neuronal cells blocks neuronal differentiation (Ishibashi et al., 1994), whereas blocking its expression stimulates neuronal differentiation (Ishibashi et al., 1995). Thus, neuronal differentiation, like other biological process, is regulated by both positive and negative factors.

The molecular regulatory mechanisms known to be operational during amphibian development were used as the theoretical basis for the present invention. The methods and cell products of the invention are based on the discovery that induced expression of a transcription factor that positively regulates human neuronal differentiation, performed in concert with the suppression of a negative regulator of human neuronal differentiation, results in the conversion of epidermal cells into newly created neurons.

The inventive method, which exploits these molecular mechanisms, results in epidermal basal cells being transdifferentiated into cells having one or more morphological, physiological and/or immunological features of a neural progenitor, neuronal or glial cell. Morphological features include, for example, neurite-like process(es) at least about 50 micrometers in length, characteristic of neuronal cells. Physiological and/or immunological features include expression of one or more specific markers and/or characteristic physiological responses to neural growth factors and other cytokines. Electrochemical characteristics of the cells, or particularly the cell membranes, are also included among physiological features, as are production and secretion by the transdifferentiated cells of regulatory factors such as dopamine or γ -aminobutyric acid (GABA), characteristic of various neuronal cell types.

In accordance with the inventive method, a proliferating epidermal basal cell population is cultured. Thus, the method of transdifferentiating or converting epidermal basal cells into newly created neural progenitors, neurons, and glial cells begins with obtaining epidermal cells from a mammalian subject's (e.g., a human patient's) skin. The cells of the proliferating epidermal basal cell population are derived from any mammalian subject, including a human subject. The cell(s) can be derived directly from a tissue sample resulting from a surgical procedure such as a skin biopsy of the subject, or can be derived indirectly from cultured or stored epidermal basal cells of the subject.

Epidermal basal cells in a skin tissue sample or in a cultured mixed population of basal and keratinized non-basal epidermal cells, are preferably separated from the terminally

differentiated keratinized epidermal cells by exposing the mixed cell population to a calcium-free growth medium. For purposes of the present invention, a calcium-free medium contains less than 10^{-6} M calcium cations (Ca^{2+}). Low calcium cation concentration results in the stripping of the keratin-forming upper epidermal layers from the basal cells. (E.g., P.K. Jensen and L. Bolund, *Low Ca^{2+} stripping of differentiating cell layers in human epidermal cultures: an invitro model of epidermal regeneration*, Experimental Cell Research 175:63-73 [1988]). The basal cells are then physically separated, selected or isolated from the keratinized cells by any convenient method, such as aspiration or decantation. Calcium cations are required to support development of keratinocytes (skin cells) from basal cells, and returning calcium to the growth medium results in rapid basal cell proliferation in the dedifferentiated cell population (Jensen and Bolund [1988]), and, thus, a proliferating epidermal basal cell population is cultured. Beyond this, it is not necessary to do a dedifferentiating step with respect to individual epidermal basal cell(s) after they are separated, isolated, or selected from the differentiated keratinized cells.

In proliferating cell types other than epidermal basal cell, however, calcium may not be necessary to support development of any particular developmental pathway that is being deregulated. Other means to achieve the desired end of dedifferentiation involve treating the cells with specific growth factor or cytokines. Also, altering the specific gene expression pathway that is responsible for differentiation of epidermal cells by genetic manipulation may be used instead of eliminating calcium in the growth media. Moreover, elimination of calcium may not be required if other than proliferating epidermal basal cells are used.

Transfecting or otherwise genetically modifying the epidermal basal cells is then done in vitro with one or more expression vector(s) containing at least one cDNA encoding a neurogenic transcription factor responsible for neural differentiation. Suitable cDNAs include the basic-helix-loop-helix activators, such as NeuroD1, NeuroD2, ASH1, and zinc-finger type activators, such as Zic3, and MyT1, or other cDNAs including bHLH and/or Zn-finger neurogenic genes. The transcription factors are preferably of human origin, but homologous, non-human counterparts can also be utilized in the invention. Sequences of such non-human counterparts of NeuroD1, NeuroD2, ASH1, Zic1, Zic3, and MyT1 are available from, for example, the GenBank database of NCBI (<http://www.ncbi.nlm.nih.gov/>). The neurogenic transcription factor gene(s) is operatively linked to a promoter of the expression vector, i.e., a transcriptional unit is formed from which the gene is transcribed, producing mRNA from which gene product is translated in the cell after gene delivery. Therefore, in accordance with the inventive method, expression of the neurogenic transcription factor(s) is preferably

controlled by a constitutively expressed eukaryotic promoter, such as a cytomegalovirus (CMV) promoter.

Gene delivery to the cell is by any suitable in vitro gene delivery method. (E.g., D.T. Curiel *et al.*, U.S. Patent Nos. 5,521,291 and 5,547,932). Typically, gene delivery involves
5 exposing a cell to a gene delivery mixture that includes preselected genetic material together with an appropriate vector, mixed, for example, with an effective amount of lipid transfecting agent (lipofection). The amount of each component of the mixture is chosen so that gene delivery to a specific species of cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1:1, although
10 other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial. Other well known gene delivery methods include electroporation or chemical methods. (E.g., M. Ostresh, *No barriers to entry: transfection tools get biomolecules in the door*, The Scientist 13(11):21-23 [1999]).

"Gene delivery agent", as used herein, means a composition of matter added to the
15 genetic material for enhancing the uptake of exogenous DNA segment(s) into a mammalian cell. The enhancement is measured relative to the uptake in the absence of the gene delivery agent. Examples of gene delivery agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake of DNA into the cell and reduce its breakdown during its passage through the cytoplasm to the nucleus of the cell.

20 An immunoliposome transfection method is a preferred means of gene delivery. Other preferred methods also yield high transfection efficiency, such as Ca-coprecipitation, or transfection using gene delivery agents such as Lipofectamine (Life Technologies), or Fugene-6 (Boehringer Mannheim, Inc.). Other preferred gene delivery agents include Lipofectin[®], DMRIE C, Cellfectin[®] (Life Technologies), LipoTAXI (Stratagene), Superfect or Effectene
25 (Qiagen). Although these are not as efficient gene delivery agents as viral agents, they have the advantage that they facilitate stable integration of xenogeneic DNA sequence into the vertebrate genome, without size restrictions commonly associated with virus-derived gene delivery agents. But a virus, or transfecting fragment thereof, can be used to facilitate the delivery of the genetic material into the cell. Examples of suitable viruses include
30 adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release

into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known viral vector systems are also useful.

The transfection step is followed by expressing, or over-expressing, at least one of the neurogenic transcription factors, while simultaneously, or near simultaneously, deactivating factors that are responsible for suppressing neuronal differentiation. This latter step is accomplished by adding to the growth medium at least one antisense oligonucleotide known to suppress neuronal differentiation, such as the human MSX1 gene and/or the human HES1 gene (or non-human, homologous counterparts), and growing the cells.

Thus, the transfected epidermal basal cell(s) are grown in the presence of at least one antisense oligonucleotide comprising a nucleotide sequence of a segment of a human MSX1 gene and/or a nucleotide sequence of a segment of a human HES1 gene, or homologous non-human counterpart of either of these, in an amount sufficient to suppress the expression of functional gene product of MSX1 or HES1. A sufficient amount of antisense oligonucleotides directed to suppressing transcription of both MSX1 and HES1 is a concentration in the medium of about 5 to 10 μ M each. Examples of useful antisense oligonucleotide sequences include the following human MSX1 antisense oligonucleotide sequences:

5'-GACACCGAGTGGCAAAGAAGTCATGTC-3' (first methionine) (MSX1-1; SEQ. ID.

NO.:13) or

5'-CGGCTTCCTGTGGTCGGCCATGAG-3' (third methionine) (MSX1-2; SEQ. ID. NO.:14); and two antisense oligonucleotides corresponding to the human HES1 open reading frame 5' sequence:

5'-ACCGGGGACGAGGAATTTTCTCCATTATATCAGC-3' (HES1-1; SEQ. ID. NO.:15)

or HES1 open reading frame middle sequence 2:

5'-CACGGAGGTGCCGCTGTTGCTGGGCTGGTGTGGTGTAGAC-3' (HES1-2; SEQ. ID. NO.:16). Other oligonucleotide sequences are also useful as long as they will hybridize to

nucleic acids comprising at least a segment of a human or homologous non-human MSX1 gene (e.g., GenBank Accession Nos. M97676 [human]; NM 002448 [human]; X62097

[chicken]; D82577.1 [*Ambystoma mexicanum*]) or at least a segment of an HES1 gene (e.g., GenBank Accession Nos. Y07572 [human]; Q04666 [rat]; P35428 [mouse]; AB019516 [newt]; AB016222 [*Saccharomyces pombe*]; U03914 [*Saccharomyces cerevisiae*]), preventing expression of functional MSX1 and/or HES1 gene products by targeting (i.e., hybridizing with) MSX1 or HES1 nucleic acids. The skilled artisan can readily find other useful MSX1

and /or HES1 oligonucleotide sequences by conducting a sequence similarity search of a genomics data base, such as the GenBank database of the National Center for Biotechnology Information (NCBI), using a computerized algorithm, such as PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, gapped or ungapped BLAST, or the "Align" program through the
5 Baylor College of Medicine server. (E.g., Altchul, S.F., *et al.*, *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*, Nucleic Acids Res. 25(17):3389-402 [1997]; Zhang, J., & Madden, T.L., *PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation*, Genome Res. 7(6):649-56 [1997]; Madden, T.L., *et al.*, *Applications of network BLAST server*, Methods
10 Enzymol. 266:131-41 [1996]; Altschul, S.F., *et al.*, *Basic local alignment search tool*, J. Mol. Biol. 215(3):403-10 [1990]).

Preferably, one or more nucleotide residues of the antisense oligonucleotides is thio-modified by known synthetic methods, used by the practitioner or by a commercial or other supplier, to increase the stability of the oligonucleotides in the culture media and in the
15 cells. (E.g., L. Bellon *et al.*, *4'-Thio-oligo-beta-D-ribonucleotides: synthesis of beta-4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase*, Nucleic Acids Res. 21(7):1587-93 [1993]; C. Leydier *et al.*, *4'-Thio-RNA: synthesis of mixed base 4'-thio-oligoribonucleotides, nuclease resistance, and base pairing properties with complementary single and double strand*, Antisense Res. Dev.
20 5(3):167-74 [1995]).

During the growing of the transfected cells, exposure to the antisense oligonucleotides is for a period long enough for MSX1 and/or HES1 proteins pre-existing in the growing cells to be degraded. For particular proteins with a relatively short half-life, the exposure period necessary is only a matter of hours to one day. Proteins with relatively long half-life require
25 longer treatments with antisense oligonucleotides. An exposure period of about two to three days generally suffices. The further course of development of the transdifferentiated cells depends on the in situ environmental cues to which they are exposed, whether in vitro, or implanted in vivo. Optionally, the transdifferentiated cell(s) are grown in a medium including a retinoid compound, such as retinoic acid or Vitamin A, and optionally a nerve growth factor
30 or neurotrophin, such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), neurotrophin (NT)-3, neurotrophin (NT)-4, or sonic hedgehog (Shh), and/or functional fragments of any of these. For example, treating newly formed neuronal cells with all-trans retinoic acid and BDNF results in development of GABAergic neurons or neuron-like cells (that express

Neurofilament M), whereas treatment with glial-conditioned media and sonic hedgehog aminoterminal peptide (Shh-N) results in development of mostly dopaminergic neuronal cells. Treatment with Shh-N promotes the differentiation of neuronal and oligodendroglial species from nestin-immunoreactive cells (uncommitted neural progenitor cells) and inhibits the antiproliferative, astroglial-inductive, oligodendroglial-suppressive effects of BMP2. (E.g.,
5 G. Zhu *et al.*, *Sonic hedgehog and BMP2 exert opposing actions on proliferation and differentiation of embryonic neural progenitor cells*, Dev. Biol. 21591):118-29 [1999]). This plasticity in response to the environmental cues allows the cells to maintain neuronal differentiation in vitro or in situ, when implanted into the mammalian subject, without the
10 further addition of antisense oligonucleotides.

In accordance with the method, expression of any neural progenitor-specific, neural-specific, and/or glial specific marker is detected by conventional biochemical or immunochemical means. Preferably, immunochemical means are employed, such as, but not limited to, enzyme-linked immunosorbent assay (ELISA), immunofluorescent assay (IFA),
15 immunoelectrophoresis, immunochromatographic assay or immunohistochemical staining.

These methods employ marker-specific polyclonal or monoclonal antibodies or antibody fragments, for example Fab, Fab', F(ab')₂, or F(v) fragments, that selectively bind any of various neural progenitor, neuronal or glial cell antigens. Antibodies targeting individual specific markers are commercially available and are conveniently used as recommended by
20 the antibody manufacturers. Markers specific to neural progenitor, neuronal, or glial cells include antigenic molecules that indicate expression of, for example, nestin, neural RNA-binding protein Musashi, neurofilament M (NF-M; Sigma, Inc.), neural-specific tubulin (Sigma, Inc.), neural-specific enolase (Incstar, Inc.), microtubule associated protein 2 (MAP2, Boehringer Mannheim), glial fibrillary acidic protein, O4, or any other detectable marker
25 specific to a neural progenitor, neuronal or glial cell.

Alternatively, expression of neural progenitor-specific, neural-specific or glial-specific markers is detected by conventional molecular biological techniques for amplifying and analyzing mRNA transcripts encoding any of the markers, such as but not limited to reverse transcriptase-mediated polymerase chain reaction (RT-PCR), transcription-mediated
30 amplification (TMA), reverse transcriptase-mediated ligase chain reaction (RT-LCR), or hybridization analysis. Nucleic acid sequences encoding markers (e.g., nestin, neural RNA-binding protein Musashi, neurofilament M, neural-specific tubulin, neural-specific enolase, microtubule associated protein 2, glial fibrillary acidic protein, O4) specific to neural progenitor, neuronal or glial cells are known and available in databases such as GenBank.

The skilled artisan can readily determine other useful marker-specific sequences for use as primers or probes by conducting a sequence similarity search of a genomics data base, such as the GenBank database of the National Center for Biotechnology Information (NCBI), using a computerized algorithm, such as PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, 5 gapped or ungapped BLAST, or the "Align" program through the Baylor College of Medicine server. (E.g., Altchul, S.F., *et al.*, *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*, Nucleic Acids Res. 25(17):3389-402 [1997]; Zhang, J., & Madden, T.L., *PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation*, Genome Res. 7(6):649-56 [1997]; Madden, 10 T.L., *et al.*, *Applications of network BLAST server*, Methods Enzymol. 266:131-41 [1996]; Altschul, S.F., *et al.*, *Basic local alignment search tool*, J. Mol. Biol. 215(3):403-10 [1990]).

Optionally, morphological criteria are additionally used to detect transdifferentiation of epidermal basal cells into neurons or neuron-like cells. For example, neurons or neuron-like cells may express neurites, or neurite-like processes, longer than three cell diameters (about 15 50 microns or longer).

The present invention also relates to a transdifferentiated cell of epidermal origin having a morphological, physiological and/or immunological feature of a neural progenitor, neuronal, or glial cell. The inventive cell can be, but is not necessarily, produced by the inventive method of transdifferentiating an epidermal basal cell into a cell having one or more 20 morphological, physiological and/or immunological features of a neural progenitor, neuronal, or glial cell (astrocyte, oligodendrocyte, or microglia). The cell includes cultured cellular progeny of a cell transdifferentiated from an epidermal basal cell.

"Neural progenitor" is an ectodermally-derived pluripotent stem cell having, as a physiological feature, a capacity, under physiological conditions that favor differentiation 25 (e.g., presence of particular neurotrophic factors), to develop one or more morphological, physiological and/or immunological features specifically associated with a neuronal or glial cell type, i.e., neurons, astrocytes (i.e., astroglia), oligodendrocytes (i.e., oligodendroglia), and microglia. For example, bipotent neural progenitor cells differentiate into astrocytes after exposure to ciliary neurotrophic factor (CNTF), or into neuronal cells after exposure to platelet-derived growth factor (PDGF). (E.g., J.K. Park *et al.*, *Bipotent cortical progenitor cells process conflicting cues for neurons and glia in a hierarchical manner*, J. Neurosci. 30 19(23):10383-89 [1999]). Some neural progenitors are "neural restricted" progenitors, which can differentiate only into neurons.

The presence of neural progenitors can be detected by functional testing under suitable

physiological conditions to determine the course of development and differentiation into neuronal or glial cells. Preferably, neural progenitor cells are identified by detecting the expression of any of several well-defined specific markers, such as the cytoskeletal protein nestin and/or neural RNA-binding protein Musashi (MSI). (E.g., T. Nagata *et al.*, *Structure, backbone dynamics and interactions with RNA of the C-terminal RNA-binding domain of a mouse neural RNA-binding protein, Musashi1*, J. Mol. Biol. 287(2):315-30 [1999]; P. Good *et al.*, *The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neural progenitor cells*, Genomics 52(3):382-84 [1998]; S. Sakakibara *et al.*, *Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell*, Dev. Biol. 176(2):230-42 [1996]).

"Neuronal" cells, or "neuron-like" cells, include cells that display one or more neural-specific morphological, physiological and/or immunological features associated with a neuronal cell type, including sensory neuronal, motoneuronal, or interneuronal cell types. The practitioner can choose, in connection with a particular application, the operative criteria or subset of specific features used for determining whether a transdifferentiated cell belongs to a particular type of neuronal population. Useful criterial features include morphological features (e.g., long processes or neurites); physiological and/or immunological features, such as expression of a set of neural-specific markers or antigens (e.g., neurofilament M, neural-specific β -tubulin, neural-specific enolase, microtubule associated protein 2, or others); synthesis of neurotransmitter(s) (e.g., dopamine; expression of tyrosine hydroxylase-- the key enzyme in dopamine synthesis; or gamma aminobutyric acid [GABA]); the presence of receptors for neurotransmitter(s); and/or physiological features such as membrane excitability and/or developmental response to particular cytokines or growth factors. An advantage of the transdifferentiated cell(s) of the invention is that it can be manipulated, in vitro in the presence of specific exogenously supplied signal molecules, or in vivo within specific microenvironments, into diverse neuronal types as defined by the practitioner's operative criteria.

A glial cell or "glial-like" cell includes a cell that has one or more glial-specific features, associated with a glial cell type, including a morphological, physiological and/or immunological feature specific to a glial cell (e.g. astrocytes or oligodendrocytes), for example, expression of the astroglial marker fibrillary acidic protein (GFAP) or the oligodendroglial marker O4.

In one embodiment, the transdifferentiated cell exhibits a lack of mitotic activity under

cell culture conditions which induce differentiation in neural progenitor cells, such as nutrient-rich medium containing neurotrophins (e.g., DMEM/F12, plus neuronal growth supplement B27 [Gibco-BRL], 10^{-7} M all-trans retinoic acid and brain derived neurotrophic factor [BDNF; 20 ng/mL], at 37°C in an atmosphere containing 5% CO₂).

5 In other embodiments, the cell is a GABAergic cell, i.e., a cell that produces gamma aminobutyric acid, the predominant inhibitory neurotransmitter in the central nervous system. For example, treating the transdifferentiated cells plated on laminin coated surface with all-trans retinoic acid (10^{-7} M) and BDNF (10 ng/mL) for 5-15 days results in development of GABAergic neurons or neuron-like cells.

10 In still other embodiments, the transdifferentiated cell is a dopaminergic cell, i.e., a cell that produces dopamine, a catecholamine neurotransmitter and hormone. These cells result from post-transdifferentiation treatment with glial conditioned media and sonic hedgehog aminoterminal peptide.

15 In one embodiment, the transdifferentiated cell has a morphological, physiological and/or immunological feature of an glial cell, such as expression of glial fibrillary acidic protein (GFAP).

20 It is a benefit of the inventive transdifferentiated cell(s) that they can be implanted into, and/or grafted to, a patient in need for use in cell therapy or gene therapy approaches to neurological injury or disease. Advantageously, the transdifferentiated cell(s) can be used directly without requiring a step for cell expansion.

25 The present invention also relates to a cell culture derived from the inventive transdifferentiated cell(s) originated from epidermal basal cells. The cell culture contains a plurality of cells that have a morphological, physiological and/or immunological feature of a neural progenitor, neuronal, or glial cell, for example, expression of one or more specific marker(s). The cell culture is maintained under culture conditions that favor the in vitro propagation of neural progenitors, neuronal, or glial cells, for example, suitable temperature, pH, nutrients, and growth factors, as known in the art. The cell culture can be manipulated to express additional or different neural-specific or glial specific-markers in the presence of specific exogenously supplied signal molecules.

30 The features and properties of the transdifferentiated cells and cell cultures of the present invention make them viable as a fundamental biotechnology tool directed to the human nervous system. Moreover, the transdifferentiated cells and cell cultures of the invention meet the technical criteria for use in cell and gene therapies directed to nervous

system disease and disorders. First, the inventive transdifferentiated cells and cell cultures can display morphological and functional features of neurons: they can develop long neurites with a growth cones at the end, they express a number of neural specific genes, and they do not continue to proliferate in conditions which induce differentiation. Therefore, for use in gene therapy and cell therapy, the transdifferentiated cells can not only deliver a single potential gene or factor, but additionally are capable of furnishing the whole infrastructure for nerve regeneration.

Second, the cultured transdifferentiated cells can be propagated as multipotential nervous system progenitor cells in conditions that favor proliferation and do not induce differentiation. Hence, these progenitor cells retain the capacity to become many different types of neurons or neuron-like cells depending upon the environmental cues to which they are exposed, for example GABAergic or dopaminergic cells. This broad plasticity suggests that, once implanted, the cells of the present invention will retain the capacity to conform to many different host brain regions and to differentiate into neurons specific for that particular host region. These intrinsic properties of the transdifferentiated neurons are different from the existing tumorigenic cell lines, where some neuronal differentiation can be induced under artificial conditions.

Third, another advantage of the inventive transdifferentiated cells and cell cultures is that there is no need for cell expansion, as is required with stem cell technology used to generate neurons for cell and gene therapies. Thus, the transdifferentiated cells of the present invention are sufficient in number (several millions of cells) for direct implantation. In summary, the unique characteristics and properties of these transdifferentiated cells and cell cultures yield an invention of significant scientific and commercial potential.

Consequently, the present invention also relates to a method of delivering locally secretable regulatory factors in vivo within the nervous system of a mammalian subject, including a human. The method involves transdifferentiating a population of epidermal basal cells from the subject, in accordance with the inventive method described above, into cells having a morphological, physiological and/or immunological feature of a neuronal cell. Epidermal basal cells of the particular subject requiring treatment with secretable regulatory factors are preferred, in order to avoid transplant rejection. Before, during, or after the transdifferentiation step, the cells are genetically modified, in vitro, by known methods as described above, with an expression vector comprising a DNA encoding a predetermined secretable regulatory factor, a biochemical precursor thereof, or an enzyme that catalyzes the biosynthesis of either the factor or a precursor, and the genetically modified cells are selected,

cultured, and implanted into the subject. Transfecting or otherwise genetically modifying the cells involves delivery of an expression vector comprising the DNA encoding the predetermined secretable regulatory factor, a precursor thereof, or an enzyme that catalyzes the biosynthesis of either the factor or a precursor. Expression of the gene for the regulatory factor, precursor, or enzyme is under the transcriptional control of a neuronal specific promoter (for example, neurofilament promoter or neural-specific enolase promoter). Enhanced secretion of the regulatory factor by the genetically modified cells results. This does not depend on the formation of functional interneuronal connections such as those that transmit electrochemical sensory, motor, or cognitive signals.

Examples of secretable regulatory factors include dopamine and neurotrophic factors, such as nerve growth factor (NGF), brain-derived growth factor (BDGF), neurotrophin-3, neurotrophin-4, insulin-like growth factor, ciliary neurotrophic factor (CNTF), or glia-derived neurotrophic factor. Nervous system disorders that can be treated using the method include Alzheimer's disease, diabetic neuropathy, taxol neuropathy, compressive neuropathy, AIDS-related neuropathy, amyotrophic lateral sclerosis, large fiber neuropathy, vincristine neuropathy, and Parkinson's disease.

Implantation of the genetically modified transdifferentiated cells is by conventional methods (e.g., stereotactic injection). Implantation is into an appropriate site within the nervous system of the subject, depending on the particular disorder being treated.

By way of example, the method is advantageous in the treatment of Parkinson's disease, which results mainly from degeneration of dopamine releasing neurons in the substantia nigra of the brain and the subsequent depletion of dopamine neurotransmitter in the striatum. The cause of this degeneration is unknown, but the motor degeneration symptoms of the disease can be alleviated by peripherally administering the dopamine precursor, L-dopa, at the early onset of the disease. As the disease continues to worsen, L-dopa is no longer effective, and currently, no further treatment is available. One promising treatment being developed is to transplant dopamine-rich substantia nigra neurons from fetal brain into the striatum of the brain of the patient. Results obtained from various clinical studies look extremely optimistic, however, it is estimated that up to 10 fetal brains are needed to obtain a sufficient number of cells for one transplant operation. This requirement renders unfeasible the wide application of the transplantation of primary fetal neurons as a therapeutic treatment modality. This problem is resolved, however, by utilizing the transdifferentiated neurons or neuron-like cells of the present invention for treatment of Parkinson's disease.

It is now widely recognized that transplantation of dopamine producing cells is the

most promising therapy of treating severe Parkinson's disease. Stable cell populations or cell lines genetically modified to produce dopamine is essential to an effective therapy. Since tyrosine hydroxylase (TH) is the key enzyme for dopamine biosynthesis, cloning the TH gene into an appropriate expression vector is a first step in the method of treatment. Human TH cDNA is cloned into a eukaryotic expression vector. After gene delivery, clones of genetically modified cells that demonstrate stable integration of the expression vector are selected for implantation purposes. Thus, transdifferentiated cells of the present invention are produced with enhanced expression of the tyrosine hydroxylase (TH) gene.

These cells are implanted into the patient's striatum or brain. The cells are typically implanted bilaterally in the caudate nucleus and putamen by using Magnetic Resonance Imaging (MRI)-guided stereotactic techniques. A stereotactic frame is affixed to the skull after administration of local anesthesia. The caudate nucleus and putamen are then visualized with MRI. Thereafter, under general anesthesia, about 10 passes with very thin stereotactic needles are made bilaterally, 4 mm apart in the caudate and putamen. The rationale for track spacing at approximately 4 mm intervals is important because fetal dopamine neuron processes grow several millimeters, reinnervating the host's striatum. Four trajectories for needle tracks in the caudate and six tracks in the putamen are calculated to avoid the posterior limb of the internal capsule. The entry points for the putamen and caudate tracks are at two different sites on the surface of the brain. The tracks to the putamen are approximately vertical with reference to a coronal plane, while the approach to the caudate is at an angle of approximately 30 degrees. After the implantation surgery, the implanted cells secrete dopamine in situ alleviating the subject's Parkinson's disease symptoms.

The present invention also relates to a method of isolating or identifying a novel nerve growth (or neurotrophic) factor that employs transdifferentiated cells of the invention. The methods involve transdifferentiating a population of proliferating epidermal basal cells into neuronal progenitor cells, neuronal cells, or glial cells; culturing the transdifferentiated cells; exposing the cultured cells, in vitro, to a potential nerve growth factor; and detecting the presence or absence of an effect of the potential nerve growth factor on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of the cells. The transdifferentiated cells are assayed in vitro to determine whether there is an effect of a potential nerve growth factor on a physiological or molecular biological property of the transdifferentiated cells. For example, which, if any, neuronal or glial cell types develop from neural progenitors, the maturation of particular cell types, and the continued support of cell survival (e.g., effect on cell numbers) can be determined. In

addition, experimental techniques, based on an electrophysiological characteristic (patch clamp, different types of intracellular recording, etc.) or molecular biological properties (gene expression profiles, organization of cytoskeleton, organization of ion channels and receptors etc.) can be used to detect the effects of potential nerve growth/neurotrophic factors on particular cell types. The potential factor can be, but need not be an isolated compound; the inventive transdifferentiated cells can be used to test, or assay, the effect, or lack thereof, of potential growth factor sources (tissue homogenates, expression cDNA library products, etc.) on the survival and functional characteristics of the cells to detect candidates for further isolation.

10 The use of transdifferentiated epidermal basal cells bypasses the difficulties in isolating and culturing neuronal cell types from the brain, and, therefore, the inventive method of identifying a novel nerve growth factor is a benefit to research in this area.

 This same advantage pertains to the inventive method of using cells transdifferentiated from epidermal basal cells to identify a potential chemotherapeutic agent (i.e., a drug) by transdifferentiating a population of epidermal basal cells into neuronal progenitor, neuronal, or glial cells by the inventive method described above; culturing the transdifferentiated cells; exposing the cultured cells, in vitro, to a potential chemotherapeutic agent; and detecting the presence or absence of an effect of the potential chemotherapeutic agent on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of said cells. An effect altering cell survival, a morphological or electrophysiological characteristic and/or a molecular biological property of the cells indicates the activity of the chemotherapeutic agent. The potential chemotherapeutic agent can be an agent intended to treat a nervous system disorder, or the method can be used to test an agent intended or proposed for treating any other type of disorder for its effects on cells possessing neural progenitor, neuronal or glial cell features. Experimental assay techniques, based on an electrophysiological characteristic (patch clamp, different types of intracellular recording, etc.) or molecular biological properties (gene expression profiles, organization of cytoskeleton, organization of ion channels and receptors etc.), as well as cell survival, can be used to detect the effects of potential chemotherapeutic agents on particular cell types. The potential chemotherapeutic agent can be, but need not be an isolated compound; the inventive transdifferentiated cells can be used to test, or assay, the effect of potential chemotherapeutic agents (tissue homogenates, expression cDNA library products, etc.) on the survival and functional characteristics of the cells to detect candidates for further isolation and development. Since epidermal basal cells transdifferentiated into neurons or neuron-like cells

in culture can express several neurotransmitters and receptor complexes, cell lines derived from these cells can be developed which, when differentiated into mature neurons, would display a unique profile of neurotransmitter receptor complexes. Such neuronal cell lines can be valuable tools for designing and screening potential chemotherapeutic agents.

5 The present invention also relates to a method of using transdifferentiated cells or cell cultures to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin, for example, Alzheimer's disease. The method is practiced in accordance with the above-described method of screening a potential chemotherapeutic agent, however, epidermal basal cells derived from a human subject diagnosed with a particular nervous
10 system disorder of genetic origin are transdifferentiated and the effect of the potential chemotherapeutic agent on a physiological or molecular biological property of the transdifferentiated cells is assayed in vitro. Different types of neuronal cells derived from transdifferentiated epidermal basal cells of the present invention will provide novel methodologies to screen potential chemotherapeutic agents. For example, using the epidermal
15 basal cells from patients with genetic defects that affect the nervous system will make it possible to manipulate environmental cues to induce the development of various types of neuronal cell populations that also carry this genetic defect. These cells can be used for screening of chemotherapeutic agents which potentially have effect on the diseased neurons or neuron-like cells displaying a specific set or profile of neurotransmitters, receptors
20 complexes, and ion channels.

Regardless of whether under a particular set of environmental conditions, in vitro, the inventive transdifferentiated cells express all the biochemical, morphological, and functional characteristics of a given neuronal population in vivo, they provide at least useful simulations of neurons for identifying, screening, or isolating promising new drugs or neural growth
25 factors. Once the potential of a chemical agent is identified by the inventive methods, then, further research can be done to verify its actual effect on particular cell populations of the nervous system and ascertain its clinical usefulness. Thus, the inventive methods of screening a potential chemotherapeutic agent are of benefit in finding and developing the next generation of pharmaceutical drugs narrowly aimed at modifying specific brain functions.

30 The present invention also relates to a kit for transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell. The kit is an assemblage of materials for facilitating the transdifferentiation of epidermal basal cells in accordance with the inventive methods.

The inventive kit preferably includes the following expression vectors and reagents: one or more expression vector(s) containing cDNA(s) encoding a neurogenic transcription factor, or fragment(s) thereof, such as NeuroD1, NeuroD2, ASH1, Zic1, Zic3, and MyT1, or non-human, homologous counterparts, at least one antisense oligonucleotide corresponding to a segment or portion of the human MSX1 gene and/or the human HES1 gene, or non-human, homologous counterparts, a retinoid and at least one neurotrophin, such as BDNF, CNTF, PDGF, NGF, NT-3, NT-4, and/or sonic hedgehog, or an active fragment of any of these. Preferably but not necessarily, the kit contains instructions for using the kit components for transdifferentiating a mammalian subject's epidermal basal cells, for example, starting with a patient's own skin cells.

The materials or components assembled in the inventive kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. The kits of the present invention preferably include instructions for using the materials or components effectively for practicing any or all of the inventive methods.

The foregoing descriptions of the methods, transdifferentiated cells, cell cultures, and kits of the present invention are illustrative and by no means exhaustive. The invention will now be described in greater detail by reference to the following non-limiting examples.

20

EXAMPLE I

Preparation of Epidermal Cell Culture and Dedifferentiation

Human adult skin was obtained from surgery procedures or skin biopsy. Before cultivation, as much as possible of the subepidermal tissue was removed by gentle scraping. Primary cultures were initiated by culturing 4-10 2x2 mm explants/35 mm tissue culture dish in Dulbecco's modified Eagle medium (GIBCO-BRL, Life Technologies, Inc.) with 15% fetal calf serum (GIBCO-BRL, Life Technologies, Inc.), 0.4 µg/ml hydrocortisone, and 10 ng/ml epidermal growth factor (Collaborative Research, Inc.). The medium was changed every three days. Thirty to thirty-five day old cultures were used for subsequent experimentation. Before transfections and further treatment, differentiated cell layers were stripped off by incubating the cultures in Ca²⁺-free minimal essential medium (GIBCO-BRL, Life Technologies, Inc.). Generally, a calcium free media contains less than 10⁻⁶ M Ca²⁺ ions. After 72 hours,

suprabasal layers were detached and removed after shaking of the culture dish. This calcium free treatment also dedifferentiates epidermal basal cells, as they loose expression of cytokeratines which are characteristic of epidermal cells. The cultures were then refed medium with normal Ca^{2+} concentration, that is, 2mM calcium ions containing all the additives, that is, FCS (15%), hydrocortisone (0.4 $\mu\text{g/ml}$), EGF (10 ng/ml), and cultured 18-24 hours at 37°C in an atmosphere containing 5% CO_2 .

EXAMPLE II

Transfections of Cultured Epidermal Cells

Epidermal basal cells were transfected using a Ca-coprecipitation protocol (GIBCO-BRL, Life Technologies, Inc.), Lipofectamine reagent (GIBCO-BRL, Life Technologies, Inc.), and immunoliposomes (Holmberg et al., 1994). Ca-coprecipitation and Lipofectamine reagent were used as indicated by manufacturer. Ten μg of either pRcCMVneo eukaryotic expression vector (Invitrogen) alone, or cloned pRcCMVneo vectors containing either β -galactosidase (CMV- β -gal), NeuroD1 (CMV-ND1), NeuroD2, (CMV-ND2), hASH1 (CMV-hASH1), Zic1 (CMV-Zic1), or hMyT1 (CMV-MyT1) cDNAs were used to transfect cells in one 35 mm tissue culture dish. All the cDNAs were cloned in our laboratory using sequence information from GenBank: Accession numbers: hNeuroD1 D82347 (SEQ. ID. NOS.:1 and 7); U50822 (SEQ. ID. NOS.:2 and 8); hNeuroD2 U58681 (SEQ. ID. NOS.:3 and 9); hASH1 L08424 (SEQ. ID. NOS.:4 and 10); hZic1 D76435 (SEQ. ID. NOS.:5 and 11); hMyT1 M96980 (SEQ. ID. NOS.:6 and 12). All of the cloned genes were of human origin.

Oligonucleotide primers were designed based on the sequences of interest and used to amplify full length cDNAs using RT-PCR techniques and human fetal brain mRNA as a template. Also, NeuroD1, NeuroD2 and hASH1 cDNAs were isolated by screening the human fetal brain cDNA library (Stratagene). All cDNA sequences were verified by sequencing and *in-vitro* translation using reticulocyte lysate an *in-vitro* translation system (Amersham).

EXAMPLE III

Preparation and Use of Antisense Olig nucleotides

Human MSX1 antisense oligonucleotides sequences

1) 5'-GACACCGAGTGGCAAAGAAGTCATGTC (first methionine) (MSX1-1; SEQ. ID.

NO.:13); and

2) 5'-CGGCTTCCTGTGGTCGGCCATGAG (third methionine) (MSX1-2; SEQ. ID. NO.:14) were synthesized. Additionally, human full length HES1 cDNA from the human fetal brain cDNA library was isolated and sequenced (Stratagene). Two antisense

5 oligonucleotides corresponding to the human HES1 open reading frame 5' sequence

1) 5'-ACCGGGGACGAGGAATTTTCTCCATTATATCAGC (HES1-1; SEQ. ID. NO.:15) and middle sequence

2) 5'-CACGGAGGTGCCGCTGTTGCTGGGCTGGTGTGGTGTAGAC (HES1-2; SEQ. ID. NO.:16) were synthesized. The preferred antisense oligonucleotides are thio-modified by
10 known methods. Therefore, thio-modified versions of these oligonucleotides corresponding to human MSX1 and human HES1 were synthesized and used to increase the stability of oligonucleotides in the culture media and in the cells.

In the experimental protocol, described below, oligonucleotides were directly added to the culture media at the concentration of 5-10 μ M. Randomly synthesized oligonucleotides
15 and oligonucleotides corresponding to the sequence of human albumin were used as controls.

EXAMPLE IV

Analytical Method to Detect Transdifferentiation

Immunohistochemical detection of neurofilament M expression was chosen as one marker for neuronal differentiation. Cells were fixed with 4% paraformaldehyde and
20 processed according to the immunohistochemical detection protocol recommended by the antibody manufacturer (Sigma, Inc.). Neurofilament M positive cells were counted by fluorescent microscopy. Several additional antibodies to neuronal antigens were used to characterize, in more detail, the nature of basal cell transdifferentiation into neurons. Antibodies against neural specific tubulin (Sigma, Inc.), neural specific enolase (Incstar, Inc.),
25 microtubule associated protein 2 (MAP2, Boehringer Mannheim), and neurofilaments Mix (Sternberger) were used as recommended by the antibody manufacturer. Antibodies against glial fibrillary acidic protein (GFAP, Incstar) were used to detect differentiation of astrocytes from epidermal basal cells. Additionally, morphological criteria were used to detect transdifferentiation of epidermal basal cells into neuronal cells. Cells with neurites, or
30 processes, longer than three cell diameters (50 microns or longer), and expressing at least one

neuronal marker (antigen), were counted as neurons.

EXAMPLE V

Transdifferentiation Protocol and Experimental Results

Various combinations of neural regulators leading to expression, or over-expression, of neurogenic bHLH and/or Zn-finger transcription factors and substantially simultaneous suppression of MSX1 and/or HES1 expression were tested to ascertain their effect on transdifferentiation of epidermal basal cells. Results of these experiments are presented in Table 1.

For these experiments, a immunoliposome transfection method is preferred, since it resulted in the highest transfection efficiency. Other methods of transfection that yield high transfection efficiency, such as Ca-coprecipitation, Lipofectamine, or Fugene-6 (Boehringer Mannheim, Inc.), known in the art, can be used instead of immunoliposomes. After transfection and antisense oligonucleotide treatments, cells were grown in the presence of all-trans retinoic acid (10^{-7} M) and BDNF (20ng/ml) for 5 days before immunostaining.

Table 1 shows the results of the transdifferentiation procedures described above leading to the conversion of epidermal basal cells into neuronal Neurofilament M-expressing cells *in-vitro*. Various combinations of simultaneous expression, or near simultaneous expression, of neurogenic bHLH and/or Zn-finger transcription factors and suppression of expression of MSX1 and/or HES1 genes were used to initiate transdifferentiation. Neurofilament M immunostaining and evaluation of the length of neurites, or processes (50 microns or longer were counted as neurites) were used to identify neuronal cells. Controls using pRCMV vector plasmid and randomly synthesized oligonucleotides, and oligonucleotides corresponding to the sequence of human albumin, showed no transdifferentiation of epidermal basal cells. Cells expressing Neurofilament M were counted by fluorescent microscopy. Five to seven fields of immuno-stained cells were counted for each treatment, each field containing 100-300 cells.

TABLE I

TRANSDIFFERENTIATION OF EPIDERMAL BASAL CELLS

<u>TREATMENT</u>	<u>% NEURONAL CELLS</u>
	<u>(i.e., % Neurofilament M expressing)</u>

30

Patent

CEDAR-044302

control, no treatment:

0

Over-expression:

	NeuroD1	0.01
	NeuroD2	0.03
5	ASH1	0
	Zic1	0
	MyT1	0
	NeuroD1+Zic1	0.04
	NeuroD2+Zic1	0.05
10	NeuroD1+NeuroD2+Zic1	0.05
	NeuroD1+MyT1	0.02
	NeuroD2+MyT1	0.03
	NeuroD1+NeuroD2+MyT1	0.05
	NeuroD1+NeuroD2+MyT1+Zic1	0.05
15	Antisense oligonucleotides:	
	MSX1-1	0
	MSX1-2	0
	HES1-1	0
	HES1-2	0
20	MSX1-1+MSX1-2+HES1-1+HES1-2	0

Combination of antisense oligonucleotides and over-expression of neurogenic factors:

	NeuroD1+NeuroD2+MSX1-1+MSX1-2	0.5
	NeuroD1+NeuroD2+HES1-1+HES1-2	0.8
	NeuroD1+NeuroD2+MSX1-1+HES1-1	7
25	Zic1+MSX1-1+MSX1-2	0.05
	Zic1+HES1-1+HES1-2	3
	MyT1+MSX1-1+MSX1-2	0.01

	MyT1+HES1-1+HES1-2	0.5
	MyT1+MSX1-1+HES1-1	0.9
	NeuroD1+Zic1+MSX1-1	11
	NeuroD1+Zic1+MSX1-1+HES1-1	20
5	NeuroD1+MyT1+MSX1-1	10
	NeuroD1+MyT1+MSX1-1+HES1-1	26
	NeuroD1+Zic1+MyT1+MSX1-1+HES1-1	25

10 In summary, transdifferentiation of epidermal cells into neurons is best achieved by the combined effect of expressing neurogenic transcription factors, which positively regulate neuronal differentiation, and antisense oligonucleotides, corresponding to negative regulators of neuronal differentiation. The experimental data indicate that a preferred method of transdifferentiation of epidermal cells into neurons includes the expression of both a bHLH and zinc finger transcription factor, which positively regulate neuronal differentiation, in the presence of at least one antisense DNA, corresponding to a negative regulator of epidermal
15 differentiation. Additionally, the expression of two bHLH transcription factors in the presence of two negative regulator antisense DNAs yielded a fairly high percentage of differentiated neurons.

EXAMPLE VI

Characterization of the Transdifferentiated Neuronal Cells

20 To further evaluate the transdifferentiation process and nature of newly formed neuronal cells, expression of several neuronal marker genes in these cells using immunostaining with specific antibodies against neuronal marker proteins were analyzed. In these experiments, the following combinations of transfection of neurogenic genes and antisense oligonucleotide treatments were used:

25 NeuroD1+Zic1+MSX1-1+HES1-1
 — NeuroD1+MyT1+MSX1-1+HES1-1 —
 NeuroD1+Zic1+MyT1+MSX1-1+HES1-1

The results of these experiments show that Neurofilament M positive transdifferentiated cells also express neural specific tubulin, neural specific enolase, and

microtubule associated protein 2. Expression of a number of neuronal antigens and morphological changes (neurites 50 microns or longer) of transdifferentiated cells shows that the procedure of transdifferentiation results in normal and viable neuronal cells that can be used in cell therapy applications. Moreover, the newly formed neuronal cells of the present invention have the morphological and functional criteria of neurons: they develop long neurites with a growth cones at the end, they express a number of neural specific genes, and they do not continue to proliferate in conditions which induce differentiation, such as, in the presence of all-trans retinoic acid (10^{-7} M) and BDNF (20ng/ml).

Finally, staining of treated epidermal cell cultures with antibodies against glial fibrillary acidic protein shows that small percentage (around 5%) of cells also express GFAP. This is an indication that transdifferentiated cells acquire characteristics of astroglial cells, either directly or indirectly. One possible explanation is that expression of neurogenic genes and blocking expression of inhibitors of neurogenesis results in formation of neuronal progenitor cells that differentiate both neurons and astroglial cells in vitro.

15

EXAMPLE VII

A Gene Therapy Application for Transdifferentiated Neuronal Cells in Parkinson's Disease

Parkinson's Disease results mainly from degeneration of dopamine releasing neurons in the substantia nigra of the brain and the resulting depletion of dopamine neurotransmitter in the striatum. The cause of this degeneration is unknown, but the motor degeneration symptoms of the disease can be alleviated by peripherally administering the dopamine precursor, L-dopa, at the early onset of the disease. As the disease continues to worsen, L-dopa is no longer effective, and currently, no further treatment is available. One promising treatment being developed is to transplant dopamine-rich substantia nigra neurons from fetal brain into the striatum of the brain of the patient. Results obtained from various clinical studies look extremely optimistic, however, it is estimated that up to 10 fetal brains are needed to obtain a sufficient number of cells for one transplant operation. This requirement renders unfeasible the wide application of the transplantation of primary fetal neurons as a therapeutic treatment modality. This problem is resolved, however, by utilizing the transdifferentiated neuronal cells of the present invention for treatment of Parkinson's disease.

It is now widely recognized that transplantation of dopamine producing cells is the most promising therapy of treating severe Parkinson's disease. Stable cell populations or cell lines genetically engineered to produce dopamine is essential to an effective therapy. Since tyrosine hydroxylase (TH) is the key enzyme for dopamine synthesis, cloning this gene in an appropriate expression vector is a first step in the method of treatment. Thus, human TH cDNA will be cloned into eukaryotic expression vector under the control of neuronal specific promoter (for example, neurofilament, neural specific enolase). Expression constructs will be transfected into epidermal basal cells of a patient, using high efficiency transfection protocols (Lipofectamine, Ca-coprecipitation etc.), followed by selection of the clones which demonstrate stable integration of the expression vector. These clones will be used for transdifferentiation procedures to obtain newly formed neurons that express TH. Thus, human neurons derived from transdifferentiated cells of the present invention will be produced which express the tyrosine hydroxylase (TH) gene. These cells will be transplanted into the patient's striatum or brain. First, the cells will be implanted bilaterally in the caudate nucleus and putamen by using Magnetic Resonance Imaging (MRI)-guided stereotactic techniques. The stereotactic frame will be fixed to the skull after administration of local anesthesia. The caudate nucleus and putamen then will be visualized with MRI. Thereafter, under general anesthesia, ten passes with very thin stereotactic needles will be made bilaterally, 4 mm apart in the caudate and putamen. The rationale for track spacing at approximately 4 mm intervals is important because fetal dopamine neuron processes grow several millimeters, reinnervating the host's striatum. Four trajectories for needle tracks in the caudate and six tracks in the putamen will be calculated to avoid the posterior limb of the internal capsule. The entry points for the putamen and caudate tracks will be at two different sites on the surface of the brain. The tracks to the putamen will be approximately vertical with reference to a coronal plane, while the approach to the caudate will be at an angle of approximately 30 degrees.

EXAMPLE VIII

A Gene Therapy Application for Transdifferentiated Neuronal Cells for the Delivery of Nerve Growth Factors to the Brain

The transdifferentiated neuronal cells of the present invention can be transfected with nucleic acids encoding nerve growth (neurotrophic) factors of potential interest. Primary examples of growth factors currently in clinical trials or under full development by various companies are listed below in Table II. So far, tests of the effects of growth factors on the

brain and nervous system have been limited to direct peripheral injection of large doses of these factors, which carries a significant risk of side effects, since most growth factors affect many different populations of neurons and non-neural tissues. These problems can be overcome by generating transdifferentiated neuronal cell lines that stably express these growth factors and secrete the growth factors after transplantation.

TABLE II

NEUROTROPIC FACTORS AND DISEASES

	<u>NEUROTROPIC FACTOR</u>	<u>DISEASE</u>
10	Nerve growth factor (NGF)	Alzheimer's Disease Diabetic neuropathy Taxol neuropathy Compressive neuropathy AIDS-related neuropathy Amyotrophic lateral sclerosis
15	Brain-derived growth factor (BDNF) Neurotrophin 3 (NT-3) Insulin-like growth factor (IGF)	Large fiber neuropathy Amyotrophic lateral sclerosis Vincristine neuropathy Taxol neuropathy Amyotrophic lateral sclerosis
20	Ciliary neurotrophic factor (CNTF) Glia-derived neurotrophic factor	Parkinson's Disease

25 Local delivery of neurotrophic factors has been suggested as a method to treat several neurological conditions (see Table II). Transdifferentiated epidermal cells from patients own skin represent a vehicle for neurotrophic factor delivery. Human neurotrophic factors cDNAs will be cloned into eukaryotic expression vector under the control of neuronal specific promoter (for example, neurofilament or neural specific enolase). Expression
30 constructs will be transfected into epidermal-basal cells using high efficiency transfection protocols (Lipofectamine, Ca-coprecipitation etc.). This procedure is followed by selection of the clones that demonstrate stable integration of expression vector. These clones will then be used for transdifferentiation procedures to obtain newly formed neurons that express particular neurotrophic factors at significantly high levels. Neuronal cells that express these

neurotrophic factors will be transplanted into the patients brain and/or nervous system, as described in Example VII, into locations which are in need of neurotrophic factor delivery.

EXAMPLE IX

A Cell Therapy Application for Transdifferentiated Neuronal Cells

5 as a Treatment for Neurotraumas, Stroke and Neurodegenerative Disease

In most neurological diseases, unlike Parkinson's Disease, the underlying cause of symptoms cannot be attributed to a single factor. This condition renders the therapeutic approach of introducing a single gene by gene therapy or single neuronal type replacement by cell therapy ineffective. Rather, replacement of the lost, or diseased, host neuronal cells, or even neuronal networks, by healthy cells and neuronal networks is required. The present invention enables us to develop different types of neurons from a patient's own epidermal basal cells. These newly formed neurons can be cultured separately, or together, to stimulate formation of functional neuronal networks that can be used for replacement therapies. Alternatively, different types of neurons can be transplanted and induced to form functional connections between themselves and host neurons, *in situ*, in the brain or in the spinal cord. Ability to differentiate *de novo*, formed neurons into variety of neuronal types *in vitro* and *in vivo* makes this approach especially powerful and useful for replacement of complex structures and networks in the nervous system.

As an example for restoring local circuitry in the nervous system is the formation of a functional "pattern generator" in the injured spinal cord. Several data demonstrate that a pattern generator functions in humans, and moreover, that physical therapy can stimulate stepping and use of legs in spinal cord injury patients. (For a review, see Wickelgren, I. 1998. Teaching the spinal cord to walk. Research News. *Science* 279, 319-321. 1998). The pattern generator involves different types of interneurons that connect sensory afferents and motoneurons. Transdifferentiated epidermal basal cells will be treated so as to form all major neuronal cell types that are required for functioning of pattern generator. Here cells will be mixed together wherein natural synapse formation will occur. Since pattern generators are composed of major excitatory (glutamatergic, cholinergic) and inhibitory (glycinergic including Renshaw cells, GABAergic) neurons, first, these neuronal types will be generated by the methods of the present invention described above. Second, excitatory and inhibitory neurons produced in the first step will be grown in co-cultures to stimulate

formation of functional connections between the neuron cells. This step will yield aggregates of cells which will be transplanted into the injured spinal cord of a patient. An alternative approach will be to develop different neuronal cell types separately, and mix these before transplantation into the spinal cord. By use of these procedures which permits the
5 transplantation of a large number of different excitatory and inhibitory neurons, a functional set of neuronal connections, capable of supporting local functions of the spinal cord will be developed.

EXAMPLE X

Use of Transdifferentiated Neuronal Cells as a Research Tool in the Search for 10 Novel Growth Factors

One of the central principles of modern neurobiology is that each of the major projection neurons, if not all neurons, requires specific signals (trophic factors) to reach their target cells and survive. Neuropathies in many diseases may be caused by, or involve lack of, such growth factors. These growth factors represent the next generation of preventative
15 and therapeutic drugs for nervous system disorders, and hence the enormous capitalization has been invested in the search and development of novel growth factors by the biotechnology industry.

Implicit in the observation that mature neurons can be produced from transdifferentiated neurons is the fact that various growth factors can be tested using these
20 cells to assay for final determination of cell types, maturation, and continued support of cell survival. Most of the growth factors known so far in the nervous system were discovered by their effects on peripheral nerves and these most likely represent a very minor fraction of existing growth factors in the brain.

Search for growth factors from the brain has been difficult mainly because particular
25 neuronal cell types are difficult to isolate from the brain and maintain in defined culture conditions. The use of transdifferentiated epidermal cells overcomes this problem and opens new assays to screen potential growth factors.

The different types of neuronal cells that are created from transdifferentiated epidermal basal cells provides a novel research tool for the discovery and analyses of the
30 effect of new, and also already characterized, growth/neurotrophic factors. Epidermal basal cells will be transdifferentiated into different types of neuronal cells characterized by a particular subtype of neurons. These specific neuronal cells will be used to test, or assay, the

effect of potential growth factor sources (tissue homogenates, expression cDNA library products, etc.) on the survival and functional characteristics of cells. For example, cell number will be counted for the analysis of survival of neuronal cells after exposure to growth factors. A wide spectrum of experimental analyses of the functional characteristics of these
5 neurons, known in the art, can be performed to assay the effect of these novel growth factors on the newly created neurons. Experimental techniques, based on an electrophysiological characteristic (patch clamp, different types of intracellular recording, etc.) and molecular biological (gene expression profiles, organization of cytoskeleton, organization of ion channels and receptors etc.) will be used to detect effects of potential growth/neurotrophic
10 factors on particular cell types.

EXAMPLE XI

Use of Transdifferentiated Neuronal Cells as a Research Tool in Drug Screening

As more and more neurotransmitter receptors and signal transducing proteins are being identified from the brain, it is becoming clear that the dogma of one neurotransmitter
15 activating one receptor is an over-simplification. Most receptor complexes in neurons are composed of protein subunits encoded by several genes and each gene synthesizes many different variations of the protein. These variations result in a wide range of possible receptor combinations, and not a single receptor that can interact with a neurotransmitter. Consequently, a range of signal output may be produced by a single neurotransmitter action.
20 The specific signal effected by a neurotransmitter on a neuron, then, depends on which receptor complex is produced by the cell. Thus, cellular diversity must parallel the molecular diversity and constitute a major structural element underlying the complexity of brain function.

Drug discovery by traditional pharmacology had been performed without the
25 knowledge of such complexity using whole brain homogenate and animals. These studies mostly produced analogs of neurotransmitters with broad actions and side effects. The next generation of pharmaceutical drugs aimed at modifying specific brain functions may be obtained by screening potential chemicals against neurons displaying a specific profile of neurotransmitters, receptors complexes, and ion channels.

30 Epidermal basal cells transdifferentiated into neurons in culture can express several neurotransmitters and receptor complexes. Cell lines derived from these cells can be

CEDAR-044302

CEDAR-044302

ed which, when differentiated into mature neurons, would display a unique profile of neurotransmitter receptor complexes. Such neuronal cell lines will be valuable tools for finding and screening potential drugs.

scope of the
understood that
several aspects of

Regardless of whether under a particular set of environmental conditions, in vitro, the in vitro transdifferentiated cells express all the biochemical, morphological, and functional characteristics of a given neuronal population in vivo, they provide at least useful simulations of neurons for identifying, screening, or isolating promising new drugs or neural growth factors. Once the potential of a chemical agent is identified by the inventive methods, then, further research can be done to verify its actual effect on particular cell populations of the nervous system and ascertain its clinical usefulness. Thus, the inventive methods of finding a potential chemotherapeutic agent are of benefit in finding and developing the next generation of pharmaceutical drugs narrowly aimed at modifying specific brain functions.

Different types of neuronal cells created from transdifferentiated epidermal basal cells of the present invention will provide novel methodologies to screen potential drugs. For example, using the epidermal basal cells from patients with genetic defects that affect the nervous system will make it possible to create various types of neuronal cells which also carry this genetic defect. These cells will be used for screening of drugs which potentially have effects on diseased neurons. Epidermal basal cells will be transdifferentiated into various types of neuronal cells with characteristics of the desired subtype of neurons. These specific neuronal cells will be used to test, or assay, the effect of potential drugs on the survival and functional characteristics of the cells. Cell number will be counted for the analysis of survival of neuronal cells after exposure to drugs. A wide spectrum of electrophysiological techniques (e.g., patch clamp, different types of intracellular recording etc.) and molecular biological (gene expression profiles, organization of cytoskeleton, organization of ion channels and receptors) techniques can be used to detect effects of potential drugs on particular cell types.

In summary, the transdifferentiation nerve cell technology of the present invention offers broad and significant potentials for treating nervous system disorders in both the areas of cell and gene therapy, as well as offering a potential new source of human neurons for research and drug-screening.

While the invention can be described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but on the contrary is intended to cover various

CLAIMS

20. Jan. 2000

1. A method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell, comprising:

5 (a) culturing a proliferating epidermal basal cell population comprising one or more epidermal basal cell(s), said cell(s) derived from the skin of a mammalian subject;

(b) transfecting said epidermal basal cell, in vitro, with one or more eukaryotic expression vector(s) containing at least one cDNA encoding a human neurogenic transcription factor, or homologous non-human counterpart, or active fragment(s) thereof, from the group consisting of
10 NeuroD1, NeuroD2, ASH1, Zic1, Zic3, and MyT1, such that at least one of the neurogenic transcription factor(s) is expressed in said cell;

(c) growing the transfected cell in the presence of at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and/or human HES1 gene, or homologous non-human counterpart of either of these, thereby suppressing at least one negative regulator of neuronal
15 differentiation; and, optionally,

(d) growing said epidermal cell with a retinoid and at least one neurotrophin selected from the group consisting of BDNF, CNTF, PDGF, NGF, NT-3, NT-4, sonic hedgehog, and active fragments of any of these, or a cytokine comprising IL-6, whereby the cell is transdifferentiated into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural
20 progenitor, neuronal, or glial cell.

2. The method of Claim 1, wherein the eukaryotic expression vector(s) of the transfection step comprise a CMV promoter sequence operatively linked to a DNA(s) encoding the neurogenic transcription factor selected from the group consisting of NeuroD1, NeuroD2, ASH1, Zic1, Zic3, and MyT1, and wherein the DNA encoding the neurogenic transcription factor is of human origin or is
25 a homologous non-human counterpart, or is an active fragment of a gene encoding any of these.

3. The method of Claim 1, wherein the physiological and/or immunological feature is expression of a marker selected from the group consisting of nestin, neural RNA-binding protein Musashi, neurofilament M, neural-specific β -tubulin, neural-specific enolase, microtubule associated protein 2, glial fibrillary acidic protein (GFAP), O4, or a combination of any of these.

30 4. The method of Claim 1, wherein the morphological feature comprises one or more morphological neurite-like process(es) at least about 50 micrometers in length.

5. A transdifferentiated cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell, comprising:

an epidermal basal cell transfected with one or more expression vectors comprising a

CMV promoter sequence operatively linked to a DNA(s) encoding the neurogenic transcription factor NeuroD1, NeuroD2, ASH1, Zic1, Zic3, or MyT1, wherein the DNA encoding the neurogenic transcription factor is of human origin, or is a non-human homologous counterpart, or is an active fragment of a gene encoding any of these, said cell being treated with at least one antisense oligonucleotide comprising a segment(s) of human MSX1 gene or human HES1 gene, or non-human homologous counterpart thereof, and wherein said cell was grown in the presence of a retinoid and at least one neurotrophin, thereby transdifferentiating said epidermal basal cell into a cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell.

6. The transdifferentiated cell of Claim 5, wherein the physiological and/or immunological feature is expression of a marker selected from the group consisting of nestin, neural RNA-binding protein Musashi, neurofilament M, neural-specific β -tubulin, neural-specific enolase, microtubule associated protein 2, glial fibrillary acidic protein (GFAP), O4, or a combination of any of these.

7. The transdifferentiated cell of Claim 5, wherein the morphological feature comprises one or more morphological neurite-like process(es) at least about 50 micrometers in length.

8. A transdifferentiated cell produced by the process of Claim 1.

9. The transdifferentiated cell of Claim 8, wherein the physiological and/or immunological feature expressed by the cell is a marker selected from the group consisting of nestin, neural RNA-binding protein Musashi, neurofilament M, neural-specific β -tubulin, neural-specific enolase, microtubule associated protein 2, glial fibrillary acidic protein (GFAP), O4, or a combination of any of these.

10. The transdifferentiated cell of Claim 8, wherein the morphological feature expressed by the cell is one or more morphological neurite-like process(es) at least about 50 micrometers in length.

11. A kit for converting epidermal basal cells to cells into cells having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell, said kit comprising:

(A) one or more eukaryotic expression vector(s) containing cDNA encoding a neurogenic transcription factor, or fragment thereof, from the group consisting of NeuroD1, NeuroD2, ASH1, Zic1, Zic3, and MyT1, or a non-human homologous counterpart of any of these;

(B) at least one antisense oligonucleotide corresponding to the human MSX1 gene, the human HES1 gene, or a non-human homologous counterpart of either of these; and

(C) a retinoid and at least one neurotrophin from the group consisting of BDNF, CNTF, PDGF, NGF, NT-3, NT-4, and sonic hedgehog.

12. The kit of Claim 11, further comprising instructions for using (A), (B), and (C) in transdifferentiating a mammalian subject's epidermal basal cell(s).

13. A method of using transdifferentiated epidermal basal cells having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell to isolate a novel nerve growth factor, comprising:

(a) transdifferentiating epidermal basal cells to cells having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell as in Claim 1;

(b) culturing the transdifferentiated cells in vitro;

(c) exposing the cultured cells, in vitro, to a potential nerve growth factor; and

(d) detecting the presence or absence of an effect of the potential nerve growth factor on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of said cells, whereby an effect altering cell survival, an electrophysiological characteristic and/or a molecular biological property in the cells indicates the action of the novel nerve growth factor.

14. A method of using transdifferentiated epidermal basal cells having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell to screen a potential new drug for treating a nervous system disorder, comprising:

(a) transdifferentiating epidermal basal cells from a patient with a nervous system disorder to cells having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell as in Claim 1;

(b) culturing the transdifferentiated cells in vitro;

(c) exposing the cultured cells, in vitro, to a potential new drug; and

(d) detecting the presence or absence of an effect of the potential new drug on the survival of the cells or on a morphological or electrophysiological characteristic and/or molecular biological property of said cells, whereby an effect altering cell survival, an electrophysiological characteristic and/or a molecular biological property in the cells indicates the action of the potential new drug factor.

15. A transdifferentiated epidermal basal cell having one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell, wherein the physiological and/or immunological feature expressed by the cell is a marker selected from the group consisting of nestin, neural RNA-binding protein Musashi, neurofilament M, neural-specific

β -tubulin, neural-specific enolase, microtubule associated protein 2, glial fibrillary acidic protein (GFAP), O4, or a combination of any of these.

5 16. The transdifferentiated cell of Claim 15, wherein the cell further displays the physiological feature of a lack of mitotic activity under cell culture conditions which induce differentiation in neural progenitor cells.

17. The cell of Claim 15, wherein the transdifferentiated cell has a morphological, physiological, or immunological feature specific to a neuronal cell.

10 18. The transdifferentiated cell of Claim 17, wherein the physiological and/or immunological feature is expression of neural RNA-binding protein Musashi, neurofilament M, neural-specific β -tubulin, neural-specific enolase, microtubule associated protein 2.

19. The transdifferentiated cell of Claim 17, wherein the cell is a GABAergic cell.

20. The transdifferentiated cell of Claim 17, wherein the cell is a dopaminergic cell.

21. The transdifferentiated cell of Claim 15, wherein the morphological feature is one or more neurite-like process(es) at least about 50 micrometers in length.

15 22. The transdifferentiated cell of Claim 15, wherein the cell is of human origin.

23. The cell of Claim 15, wherein the transdifferentiated cell has a morphological, physiological, or immunological feature specific to an astroglial or oligodendroglial cell.

24. The transdifferentiated cell of Claim 23, wherein the physiological and/or immunological feature is expression of glial fibrillary acidic protein (GFAP) or O4.

20 25. A cell culture derived from the transdifferentiated cell of Claim 15, comprising a plurality of cells that express one or more morphological, physiological and/or immunological feature(s) of a neural progenitor, neuronal, or glial cell.

25 26. The method of Claim 1, wherein culturing a proliferating epidermal basal cell population comprising one or more epidermal basal cell(s) comprises separating basal cells from keratinocytes using a calcium-free medium.

27. The method of Claim 1, wherein said antisense oligonucleotide(s) is modified with one or more thio groups.

A



B



C



Figure 1.

SEQUENCE LISTING

EPO - Munich
24

20. Jan. 2000

<110> Cedars-Sinai Medical Center
Michel F. Levesque, M.D.
Toomas Neuman, Ph.D.

<120> Transdifferentiation of Transfected Epidermal
Basal Cells Into Neural Progenitor Cells, Neuronal Cells
And/Or Glial Cells

<130> CEDAR 044302

<140> 09/234,332

<141> 1999-01-20

<160> 16

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2502

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (0)...(0)

<223> Neuro D1 gene: Genbank accession D82347

<400> 1

cggccacgac	acgaggaatt	cgccccacgca	ggaggcacgg	cgtccggagg	ccccaggggtt	60
atgagactat	cactgctcag	gacctactaa	caacaaagga	aatcgaaaca	tgaccaaattc	120
gtacagcgag	agtgggctga	tgggcgagcc	tcagcccca	ggctctccaa	gctggacaga	180
cgagtgtctc	agttctcagg	acgaggagca	cgaggcagac	aagaaggagg	acgacctcga	240
agccatgaac	gcagaggagg	actcactgag	gaacggggga	gaggaggagg	acgaagatga	300
ggacctggaa	gaggaggaag	aagaggaaga	ggaggatgac	gatcaaaagc	ccaagagacg	360
cggcccaaaa	aagaagaaga	tgactaaggc	tcgcctggag	cgttttaaat	tgagacgcat	420
gaaggctaac	gcccgggagc	ggaaccgcat	gcacggactg	aacgcggcgc	tagacaacct	480
gcgcaagggtg	gtgccttgct	attctaagac	gcagaagctg	tccaaaatcg	agactctgcg	540
cttggccaag	aactacatct	gggctctgtc	ggagatcctg	cgctcaggca	aaagcccaga	600
cctgggtctcc	ttcgttcaga	cgctttgcaa	gggcttatcc	caaccacca	ccaacctggt	660
tgggggctgc	ctgcaactca	atcctcggac	ttttctgcct	gagcagaacc	aggacatgcc	720
ccccacctg	ccgacggcca	gcgcttcctt	ccctgtacac	ccctactcct	accagtgcgc	780
tgggctgccc	agtccgcctt	acgggtaccat	ggacagctcc	catgtcttcc	acgttaagcc	840
tccgccgcac	gcctacagcg	cagcgctgga	gcccttcttt	gaaagccctc	tgactgattg	900
caccagccct	tcctttgatg	gacccctcag	cccgccgctc	agcatcaatg	gcaacttctc	960
tttcaaacac	gaaccgtccg	ccgagtttga	gaaaaattat	gcctttacca	tgactatccc	1020
tgcagcgaca	ctggcgaggg	cccaaagcca	cggatcaatc	ttctcaggca	ccgctgcccc	1080
tcgctgcgag	atccccatag	acaatattat	gtccttcgat	agccattcac	atcatgagcg	1140
agtcatgagt	gcccagctca	atgccatatt	tcattgattag	aggcagccca	gtttcaccat	1200
ttccgggaaa	cgaaccact	gtgcttacag	tgactgtcgt	gtttacaaaa	ggcagccctt	1260

tggttactac	tgctgcaaag	tgcaaatact	ccaagcttca	agtgatatat	gtattttattg	1320
tcattactgc	ctttggaaga	aacaggggat	caaagttcct	gttcacctta	tgtattatttt	1380
tctatagctc	ttctatttta	aaaataaaaa	aatacagtaa	agtttaaaaa	atacaccacg	1440
aattttggtg	ggctgtattc	agatcggtatt	aattatctga	tcgggataac	aaaatcacaa	1500
gcaataatta	ggatctatgc	aattttttaa	ctagtaatgg	gccaatataa	atatatataa	1560
atatatattt	ttcaaccagc	atctttactac	ttgttacctt	tcccatgctg	aattattttg	1620
ttgtgatttt	gtacagaatt	tttaatgact	ttttataatg	tggatttcct	atctttaaacc	1680
catgcagctt	catcaatttt	tatacatatc	agaaaagtag	aattatatct	aattttatata	1740
aaataattta	actaatttta	accagcagaa	aagtgcctag	aaagttattg	tgttgcctta	1800
gcacttcctt	cctctccaat	tgtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaattg	1860
cacaatttga	gcaatttcatt	tcacttttaa	gtctttccgt	ctccctaaaa	taaaaaccag	1920
aatcataatt	ttcaagagga	gaaaaaatta	agagatacat	tccctatcac	aacatatcaa	1980
ttcaacacat	tacttgacac	agcttgtata	tacatattat	aaatagatgc	caacataccc	2040
ttcttttaaa	cacaagctgc	ttgactatca	catacaattt	gcactgttac	tttttagtct	2100
tttactcctt	tgcattccat	gatttttacag	agaatctgaa	gctattgatg	tttccagaaa	2160
atataaatgc	atgattttat	acatagtcac	ccccatggtg	ggttgtcata	tattcatgta	2220
ataaatctga	gcctaaatct	aatcaggttg	ttaatgttgg	gagttatatc	tatagtagtc	2280
aattagtaga	gtagctttaa	taaattcccc	ccatttaatt	cataattaga	acaatagcta	2340
ttgcatgtaa	aatgcagtc	agaataagtg	ctggttgaga	tgtgatgctg	gtaccactgg	2400
aatcgatctg	tactgtaatt	ttgtttgtaa	tcctgtatat	tatggtgtaa	tgcaaatatt	2460
agaaaacatt	catccagttg	caataaaaata	gtattgaaag	tg		2502

<210> 2

<211> 1676

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (0)...(0)

<223> Neurogenic helix-loop-helix protein (Neurod 1)
gene

Genbank accession J50822

<400> 2

acatcgatta	actttttctc	agaggcattc	atctttgtaat	gggcaggtag	ttttcgcaag	60
cattttgtaca	ggttttagga	gtggaagctg	aaggcgatct	ttcttttgat	atagcgtttt	120
tctgcttttc	tttctgtttg	cctctccctt	gttgaatgta	ggaaatcgaa	acatgaccaa	180
atcgtagacg	gagagtgggc	tgatgggcga	gcctcagccc	caaggtcctc	caagctggac	240
agacgagtg	ctcagttctc	aggacgagga	gcacgaggca	gacaagaagg	aggacgacct	300
cgaagccatg	aacgcagagg	aggactcact	gaggaacggg	ggagaggagg	aggacgaaga	360
tgaggacctg	gaagaggagg	aagaagagga	agaggaggat	gacgatcaaa	agcccaagag	420
acgcggcccc	aaaaagaaga	agatgactaa	ggctcgccctg	gagcgtttta	aattgagacg	480
catgaaggct	aacgcccggg	agcggaaccg	catgcacgga	ctgaacgcgg	cgctagacaa	540
cctgcgcaag	gtggtgcctt	gctattctaa	gacgcagaag	ctgtccaaaa	tcgagactct	600
gcgcttgagg	aagaactaca	tctgggctct	gtcggagatc	tcgcgctcag	gcaaaaagccc	660
agacctggtc	tccttcgttc	agacgctttg	caagggtctta	tcccaaccca	ccaccaacct	720
ggttgcgggc	tgcttgcaac	tcaatcctcg	gacttttctg	cctgagcaga	accaggacat	780
gccccgcac	ctgccgacgg	ccagcgcttc	cttccctgta	caccctact	cctaccagtc	840
gcctgggctg	cccagtcgcg	cttacggtac	catggacagc	tcccatgtct	tccacgttaa	900
gcctccgccc	cacgcctaca	gcgcagcgct	ggagcccttc	tttgaaagcc	ctctgactga	960
ttgcaaccagc	ccttcctttg	atggacccct	cagcccgccg	ctcagcatca	atggcaactt	1020
ctcttttcaa	cacgaaccgt	ccgccgagtt	tgagaaaaat	tatgccttta	ccatgcacta	1080
tcctgcagcg	acactggcag	gggcccacaa	ccacggatca	atcttctcag	gcaccgctgc	1140


```

ccctcgetgc gagatcccca tagacaatat tatgtccttc gatagccatt cacatcatga 1200
gcgagtcacg agtgccacgc tcaatgccat atttcatgat tagaggcacg ccagtttcac 1260
catttcgggg aaacgaaccc actgtgctta cagtgaactgt cgtgtttaca aaaggcagcc 1320
ctttggtact actgctgcaa agtgcaata ctccaagctt caagtgatat atgtatttat 1380
tgtcattact gccttttgaa gaaacagggg atcaaagtgc ctgttcacct tatgtattat 1440
tttctataga ctcttctatt ttaaaaaata aaaaaatata gtaaagttta aaaaatacac 1500
cacgaatttg gtgtggctgt attcagatcg tattaattat ctgatcgga taacaaaatc 1560
acaagcaata attaggatct atgcaatttt taaactagta atgggccaat taaaatatat 1620
ataaatatat atttcaacca gcattttact acttggttacc tcccatgctg aattat 1676

```

<210> 3

<211> 1550

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (0)...(0)

<223> Neurogenic basic-helix-loop-helix protein (Neuro
D2) gene Genbank Accession U58681

<221> unsure

<222> (1219)...(1226)

<223> n at 1219 and 1226; n = A, T, G, or C

<400> 3

```

cccccaactt tgtgtgtgtt gtctccctt cccgcccgcg gggcgccctc aggcaccatg 60
ctgaccgcgc tgttcagcga gcccgccctt ctctcggaag tgcccaagtt cgccagctgg 120
ggcgacggcg aagacgacga gccgaggagc gacaagggcg acgcgcccgc accgccaccg 180
cctgcgcccg ggccaggggc tccggggcca gcccgggcgg ccaagccagt cctctccgt 240
ggagaagagg ggacggaggc cacgttgcc gaggtcaagg aggaaggcga gctgggggga 300
gaggaggagg aggaagagga ggaggaagaa ggactggacg aggcggaggg cgagcggccc 360
aagaagcgcg ggcccaagaa gcgcaagatg accaaggcgc gcttggagcg ctccaagctt 420
cggcggcaga aggcgaacgc gcgggagcgc aaccgcacgc acgacctgaa cgcagccctg 480
gacaacctgc gcaagggtgt gccctgttac tccaagacgc agaagctgtc caagatcgag 540
acgctgcgcc tagccaagaa ctatatctgg gcgctctcgg agatcctgcg ctccggcaag 600
cggccagacc tagtgtccta cgtgcagact ctgtgcaagg gtctgtcgca gccaccacc 660
aatctggtgg ccggtgtgtt gcagctcaac tctcgcaact tcctcacgga gcaaggcgcc 720
gacggtgccg gccgcttcca cggctcgggc ggcccgttcg ccatgcaccc ctaccgctac 780
ccgtgctcgc gcctggcggg cgcacagtgc caggcgcccg gcggcctggg cggcgggcgc 840
gcgcacgccc tgcggaccca cggctactgc gccgcctacg agacgctgta tgcggcgga 900
ggcgggtggc gcgcgagccc ggactacaac agctccgagt acgagggcc gtcagcccc 960
ccgctctgtc tcaatggcaa cttctcactc aagcaggact cctcgcccga ccacgagaaa 1020
agctaccact actctatgca ctactcggcg ctgcccgtt cgcgggccac gggccacggg 1080
ctagtcttcg gctcgtcggc tgtgcgcggg ggcgctccact cggagaatct cttgtcttac 1140
gatatgcacc ttcaccacga ccggggcccc atgtacgagg agctcaatgc gttttttcat 1200
aactgagact tcgcgcccnc tccctncttt ttcttttgcc tttgcccgc ccctgtccc 1260
cagccccag agcgagggga ccccccatc ctaccccggc gccgggcgcg gggagcgggc 1320
caccggctct gccgctctcc tggggcagcg cagtctgtt acctgtgggt ggctgtccc 1380
aggggcctcg cttccccag gggactcgcc ttctctcccc aagggttcc ctcctctct 1440
ctcccaagga gtgtttctcc agggacctct ctccgggggc tccctggagg cacctctccc 1500
ccattcccaa tatcttcgct gaggtttcct cctccccctc ctccctgcag 1550

```

<210> 4
 <211> 1635
 <212> DNA
 <213> Homo sapiens

<220>
 <221> gene
 <222> (0)...(0)
 <223> Achoaete scute homologous protein (ASH1) gene;
 Genbank accession L08424

<400> 4

cccagagacc	ggcgcaagag	agcgagcct	tagtaggaga	ggaacgcgag	acgcggcaga	60
gcgcgttcag	cactgacttt	tgctgctgct	tctgcttttt	tttttcttag	aaacaagaag	120
gcgccagcgg	cagcctcaca	cgcgagcgcc	acgcgaggct	cccgaagcca	acccgcgaag	180
ggaggaggagg	agggaggagg	aggcgggcgtg	caggaggagg	aaaaagcatt	ttcacctttt	240
ttgctcccac	tctaagaagt	ctcccgggga	ttttgtatat	attttttaac	ttccgtcagg	300
gtccccgctt	catatttctt	tttctttccc	tctctgttcc	tgcacccaag	ttctctctgt	360
gtccccctcg	cgggccccgc	acctcgcgtc	ccggatcgct	ctgattccgc	gactccttgg	420
ccgccgctgc	gcatggaaag	ctctgccaaag	atggagagcg	gcggcgccgg	ccagcagccc	480
cagccgcagc	cccagcagcc	cttcctgccc	cccgcagcct	gtttctttgc	cacggccgca	540
gccgcggcgg	ccgcagccgc	cgcagcggca	gcgcagagcg	cgcagcagca	gcagcagcag	600
cagcagcagc	agcagcagca	gcaggcgccg	cagctgagac	cggcgggcca	cggccagccc	660
tcaggggggc	gtcacaagtc	agcgcccaag	caagtcaagc	gacagcgctc	gtcttcgccc	720
gaactgatgc	gctgcaaacg	ccggtcaaac	ttcagcggct	ttggctacag	cctgccgcag	780
cagcagccgg	ccgccgtggc	gcgccgcaac	gagcgcgagc	gcaaccgcgt	caagttgggc	840
aacctgggct	ttgccaccct	tcgggagcac	gtccccaacg	gcgcggccaa	caagaagatg	900
agtaaggtgg	agacactgcg	ctcggcggtc	gagtacatcc	gcgcgctgca	gcagctgctg	960
gacgagcatg	acgcggtgag	cgccgccttc	caggcaggcg	tcctgtcgcc	caccatctcc	1020
cccaactact	ccaacgactt	gaactccatg	gccggctcgc	cggctctcatc	ctactcgctg	1080
gacgagggct	cttacgacct	gctcagcccc	gaggagcagg	agcttctcga	cttcaccaac	1140
tggttctgag	gggctcggcc	tggtcaggcc	ctgggtgcga	tggaactttgg	aagcaggggtg	1200
atcgcacaa	ctgcatcttt	agtgcctttt	tgtcagtggc	gttgggaggg	ggagaaaagg	1260
aaaagaaaaa	aaaagaagaa	gaagaagaaa	agagaagaag	aaaaaaacga	aaacagtcaa	1320
ccaaccccat	cgccaactaa	gcgaggcatg	cctgagagac	atggctttca	gaaaacggga	1380
agcgctcaga	acagtatctt	tgcactccaa	tcattcacgg	agatatgaag	agcaactggg	1440
acctgagtca	atgcgcaaaa	tgcagcttgt	gtgcaaaagc	agtgggctcc	tggcagaagg	1500
gagcagcaca	cgcggttatag	taactcccat	cacctctaac	acgcacagct	gaaagttctt	1560
gctcggttcc	cttcacctcc	ccgccctttc	ttagagtgca	gttcttagcc	ctctagaaac	1620
gagttggtgt	cttttc					1635

<210> 5
 <211> 3138
 <212> DNA
 <213> Homo sapiens

<220>
 <221> gene
 <222> (0)...(0)
 <223> Zic 1 Protein gene; Genbank Acession D76435

<400> 5

cggggtgccat	gcagctttct	ctaatttgct	ctcagttcct	ggctatgaat	tgctaaacta	60
tcagttctgc	gctcaccgcc	cggctgagga	ggtgaaagtt	tctccccagg	aagataaacc	120

gcaaaagaca	tatattgtgc	atgattttgcg	cctttttcttt	ggcttttttct	ttcttttcttc	180
acccccccac	ccactttttt	tttttttttt	ttcaaaaagc	agagagggaa	aaacggagag	240
tgaaggagcg	aggaggcgag	cgtgagagaa	aggagagaga	gagaaaagaa	agggcgaggg	300
gctagtggag	gaaggaagga	ggggcggtg	cgcgaggcg	agagagggcg	aagcagtcgc	360
ggcactggcg	ctcacattcc	tctatgtctac	aaatccagga	ggaagttttt	ttttaggggg	420
ctgagatgct	ccatgccttt	aaaagggcag	ccttgacgcg	cgccctctc	ggcagagact	480
gagcggcgag	aaagtgcgag	ccgggcccgc	agaatctgcc	tggcgggcgc	tggagcctgc	540
gttactcgcg	gccccgagcc	gtccggctac	tttgcgtttg	gccccggccag	cgccgcgcgg	600
cgcgcgcgcg	ccattgcctg	caggctagga	cttcgcgagg	tgggtcgact	cacctctcct	660
cctcctcttc	ttcctcctct	tctcctcct	cttgttctct	ctcctcctcc	cgattttccc	720
tctcgggctg	gcgagggtgg	ggggggcggg	ggaggccggg	gctcgccccg	agcagccacg	780
atgctccttg	acgcgcggccc	ccagtaccca	gcgatcggcg	tgaccacctt	tggcgcgctc	840
cgccaccact	ccgcgggcga	cgtggccgaa	cgagacgtgg	gcctgggcat	caaccggttc	900
gccgacggca	tgggcgcctt	caagctcaac	cccagttcgc	acgagctggc	ttcggccggc	960
cagacagcct	tcacgtcgca	ggcgccaggc	tacgcggctg	ctgcggccct	ggggcatcac	1020
catcacccgg	gccacgtcgg	ctcctattcc	agcgagcct	tcaactccac	gcgggacttt	1080
ctgttccgca	accgggggtt	tggcgacgcg	gcggcggcag	ccagcgca	gcacagcctc	1140
tttgctgcat	cggccggggg	cttcgggggc	ccacacggcc	acacggacgc	cgccggccac	1200
ctcctcttcc	ccgggcttca	cgagcaggct	gccggccacg	cgtcgcctaa	cgtggtcaac	1260
gggcagatga	ggctcggctt	ctcgggggac	atgtaccgcg	gaccggagca	gtacggccag	1320
gtgaccagcc	cgcgttcgga	gcactatgct	gcgcgcgagc	tgacaggcta	cgggcccatg	1380
aacgtgaaca	tggccgcgca	tcacggcgcc	ggcgcttct	tccgctacat	gcgccaaccc	1440
atcaagcaag	agctcatctg	caagtggatc	gagcccgagc	agctggccaa	ccccaaaaag	1500
tcgtgcaaca	aaactttcag	caccatgcac	gagctagtta	cgcacgtcac	cgtggagcac	1560
gtaggtggcc	cggagcagag	taatcacatc	tgtttctggg	aggagtgtcc	gcgcgagggc	1620
aagcccttca	aagccaaata	caaactggtt	aaccacatcc	gcgtgcacac	gggcgagaag	1680
ccctttccct	gccccctccc	tggctgtggc	aaggctcttcg	cgcgctccga	gaattttaaag	1740
atccacaaaa	ggacgcacac	aggggagaag	cccttcaagt	gcgagtttga	gggctgtgac	1800
cggcgcttcg	ctaacagcag	cgaccgcaag	aagcacatgc	acgtgcacac	gagcgacaag	1860
ccctatcttt	gcaagatgtg	cgacaagtcc	tacacgcata	ccagtccgt	gcgcaaacac	1920
atgaaggctc	acgaatcctc	ctcgcagggc	tgcgagcctt	cgcgggcccgc	cagctctggc	1980
tacgaatcct	ccacgcctcc	caccatcgtg	tctccctcca	cagacaaccc	gaccacagac	2040
tccttatcgc	cctcctcctc	cgcagtcac	cacacagccg	gccacagtgc	gctctcttcc	2100
aattttaacg	aatggtacgt	ttaaaatcag	aaacaaaaa	tcgaacaaaa	ccctatttaa	2160
gagacttgat	cacacacgta	tacacaacat	tactgaaaga	accctgcgaa	tcaaaacaac	2220
ccccacacag	accccgcaat	cctcttttaa	aaaatctgcc	aatagaccca	ggacgagtaa	2280
gagaggaagc	atcaaccttt	taaaaatttc	ctttcgcttt	cattattttt	ctttttttgg	2340
caaaggcttg	gtacccaagg	tgcggtaggg	ggtcgagggg	gaggaggcca	cctgaccaaa	2400
tgcgcgcaac	cccagaggcc	agtctcttgt	cgaattggta	cgggctctct	ggggcttcgg	2460
cttctttttt	tctttgtttt	cttgtaaata	cagaattatt	agcttaaaac	tgtactgttg	2520
aattctgtaa	atagttatat	ctcggttgga	gcgggtgggt	gggattgtgg	cgttgtggtc	2580
tttgcatctg	gggagggggg	agggaccgga	tgggccccgg	gagggggagg	gggaggggtg	2640
ggcgcccgaa	agccaaactgt	ttgtactgaa	tggcaagaat	gttctagtaa	atgtgtacca	2700
aaatgtgaat	tactttgtac	gattacagtc	tccacgtcga	cctaacccaa	tattattggt	2760
attaatgtgc	tttttttgta	taaagtgcga	acatttcgtc	ccaaagtcta	agtactttag	2820
tgcagtaaaa	tgttgtttca	tgtcctgtca	agaattcgta	tagtacgagc	ctggatctgc	2880
gtgtcaaaact	gttccatttg	tttatgtaaa	gtgatattaa	aaaagatata	aactataact	2940
gtccgttact	tttggaacaa	gatacaacca	cataatgtat	ataattccta	gtttccatat	3000
ttatccgcat	gtaaagggcc	ggtttatcca	tgttacagct	cttcaatatt	tatggctaga	3060
agaactcgta	tgtacacttt	agtttcgaga	actgtttggg	aacctttcgt	accttattaa	3120
agattcttaa	atctcaaa					3138

<210> 6

<211> 2623

<212> DNA
 <213> Homo sapiens

<220>
 <221> gene
 <222> (0)...(0)
 <223> Myelin transcription factor 1 (MyT1) gene Genbank
 Accession M96980

<400> 6

cggaagagtt	actacagtaa	agatccttca	agagctgaga	agcgtgagat	caagtgtcca	60
acaccaggct	gtgatggcac	tggccacggt	accgggttgt	accctcacca	ccgcagcctt	120
tctggctgtc	cccacaagga	taggatcccc	ccagagatct	tagccatgca	tgagaacgtg	180
ctgaagtgcc	ccactcctgg	ctgcacaggc	cagggtcacg	tgaacagcaa	ccgcaacacg	240
cacagaagtt	tgtctgggtg	tcccattgct	gccgccgaaa	aattagccaa	atcccatgag	300
aagcagcagc	cgcagacagg	agatccttcc	aagagtagct	ccaattccga	tccggtacctc	360
aggcccatgt	gcttcgtgaa	gcagctcgag	gtccctccat	atgggagcta	ccggcccaac	420
gtggccccc	gccacaccca	gggccaactt	ggcaaggagc	tggaagaagt	ctccaagggtc	480
acctttgact	acgcaagttt	cgatgctcag	gtttttggca	aacgcagtgt	tgccecaaaag	540
attcagacca	gcgaaacctc	acctaaagcc	tttcaatcca	aacctttccc	aaaggcctct	600
tccccagggc	acagcccctc	cagtagttat	gtgaggagca	cttcaccttc	ttctgcaggc	660
tttgactact	cgcaggacgc	cgaggctgca	cacatggctg	ccactgccat	cctgaacctc	720
tccacgcgct	gctggggagat	gcctgagaac	ctcagcacga	agccacagga	cctccccagc	780
aagtctgttg	atatecaggt	agacgaaaa	ggaacctctg	acttgagcat	gcacaaacac	840
cgcaaacgag	aaaatgcttt	ccccagcagc	agcagctgca	gcagcagccc	gggtgtgaag	900
tctcccagcg	cctcccagcg	ccacagcagc	accagcgcgc	ccagcagctc	catgacctct	960
ccccagtcca	gccaggcctc	ccgccaggac	gagtgaggac	ggcccttggg	ctacaccaag	1020
cctagccgcc	tgagagagga	ggaacctgag	gagtcagagc	cagcagccca	ttcttttgct	1080
tcttctgaag	cagatgacca	ggaagtgtcg	gaagagaatt	ttgaggagcg	gaagtatccg	1140
ggggaagtca	ccctgacca	ctttaagctg	aagtttctct	ccaaggacat	aaagaaggag	1200
ctgctcacct	gtcccacccc	tggctgtgac	ggcagcggcc	acatcaccgg	gaactacgcc	1260
tcccaccgca	gcctctctgg	ttgccctctt	gctgacaaga	gcctcagaaa	cctcatggct	1320
accactctg	ctgacctgaa	gtgcccacg	cccggctgtg	acggctcttg	ccacatcaca	1380
gggaactacg	cttcacaccg	gagcttgtcc	ggctgccttc	gtgcaaagaa	aagtggagtc	1440
aaggtggcac	ccaccaagga	cgacaaggag	gaccccgagc	tgatgaagtg	cccagttcca	1500
ggctgtgtgg	ggctcgggtca	catcagcggg	aaatacgcct	ctcacaggag	cgcattccggc	1560
tgcccactgg	ccgcccgcag	gcagaaggaa	gggtccctca	atggctcgtc	attctcctgg	1620
aagtccttga	agaatgaaga	cccgaacctg	cccaccccgg	gctgtgacgg	ctctggccac	1680
accattggga	gtttcctcac	ccaccggagt	ttgtcaggct	gtcccagagc	aacctttgct	1740
ggaaagaagg	gaaaactgtc	aggggatgag	gtcctcagtc	caaagttcaa	gactagcgac	1800
gtgttgagga	atgatgagga	gatcaagcag	ctgaaccagg	agatccgaga	cctgaacgag	1860
tccaactcgg	agatggaggc	tgccatgggtg	cagctgcagt	cccagatctc	ctccatggag	1920
aagaacctga	agaacatcga	ggaggagaac	aagctcattg	aggagcagaa	tgaagccctg	1980
tttctggagc	tgtccggcct	gagccaggcc	ctcatccaaa	gtctcgccaa	tatccacctt	2040
ccacacatgg	agccaatatg	cgaacagaat	ttcgttccct	atgtgagcac	cctcaccgac	2100
atgtactcca	accaggcccc	ggagaacaag	gacctcctgg	agagcatcaa	gcaggctgtg	2160
aggggcatcc	aggtctaggc	cgtgtggtac	ccagaagtgt	cccagccccc	cacaccgttt	2220
acctccctcg	ccctgccccg	caccgtgggg	atgcccaact	cacagtgact	tcccgtttgg	2280
ggcccgggtgt	ggcgcggggc	ggtttatcca	aagggtatgg	tggaatttgg	ccgtccccac	2340
gaggtccct	ccaggcttgg	ccgtgggtgg	cctatctgtg	tgcatagggg	cactgaagaa	2400
ttacaaagtg	atattatatt	gttttctgaa	agaaatctga	agagcagctc	aaagtctcca	2460
gtggaagctc	atggacaagg	ttctcaggga	agttttggag	tttgcaacca	cagtattcct	2520
ttgtctgtcg	aggctgggag	ggtagccgtg	agcgtgggtg	gtgggtgggtg	tgagtggcat	2580
cttggccctg	agtacacgcc	tggggcagcg	tgtctgtgct	cag		2623

<210> 7
 <211> 356
 <212> PRT
 <213> Homo sapiens

<220>
 <221> PEPTIDE
 <222> (0)...(0)
 <223> Neuro D1 protein; Genbank Accession D82347

<400> 7
 Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro
 1 5 10 15
 Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu
 20 25 30
 Glu His Glu Ala Asp Lys Lys Glu Asp Asp Leu Glu Ala Met Asn Ala
 35 40 45
 Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Asp Glu Asp Glu
 50 55 60
 Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Asp Gln Lys
 65 70 75 80
 Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
 85 90 95
 Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
 100 105 110
 Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
 115 120 125
 Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
 130 135 140
 Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile Leu Arg Ser Gly
 145 150 155 160
 Lys Ser Pro Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly Leu
 165 170 175
 Ser Gln Pro Thr Thr Asn Leu Val Gly Gly Cys Leu Gln Leu Asn Pro
 180 185 190
 Arg Thr Phe Leu Pro Glu Gln Asn Gln Asp Met Pro Pro His Leu Pro
 195 200 205
 Thr Ala Ser Ala Ser Phe Pro Val His Pro Tyr Ser Tyr Gln Ser Pro
 210 215 220
 Gly Leu Pro Ser Pro Pro Tyr Gly Thr Met Asp Ser Ser His Val Phe
 225 230 235 240
 His Val Lys Pro Pro Pro His Ala Tyr Ser Ala Ala Leu Glu Pro Phe
 245 250 255
 Phe Glu Ser Pro Leu Thr Asp Cys Thr Ser Pro Ser Phe Asp Gly Pro
 260 265 270
 Leu Ser Pro Pro Leu Ser Ile Asn Gly Asn Phe Ser Phe Lys His Glu
 275 280 285
 Pro Ser Ala Glu Phe Glu Lys Asn Tyr Ala Phe Thr Met His Tyr Pro
 290 295 300
 Ala Ala Thr Leu Ala Gly Ala Gln Ser His Gly Ser Ile Phe Ser Gly
 305 310 315 320
 Thr Ala Ala Pro Arg Cys Glu Ile Pro Ile Asp Asn Ile Met Ser Phe
 325 330 335
 Asp Ser His Ser His His Glu Arg Val Met Ser Ala Gln Leu Asn Ala

```

          340          345          350
Ile Phe His Asp
          355

<210> 8
<211> 356
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (0)...(0)
<223> Neurogenic basic helix-loop-helix protein (Neurod
        1); Genbank Accession U50822.

<400> 8
Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro
 1          5          10          15
Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu
          20          25          30
Glu His Glu Ala Asp Lys Lys Glu Asp Asp Leu Glu Ala Met Asn Ala
          35          40          45
Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Asp Glu Asp Glu
          50          55          60
Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Asp Gln Lys
          65          70          75          80
Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
          85          90          95
Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
          100          105          110
Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
          115          120          125
Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
          130          135          140
Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile Ser Arg Ser Gly
          145          150          155          160
Lys Ser Pro Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly Leu
          165          170          175
Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu Gln Leu Asn Pro
          180          185          190
Arg Thr Phe Leu Pro Glu Gln Asn Gln Asp Met Pro Pro His Leu Pro
          195          200          205
Thr Ala Ser Ala Ser Phe Pro Val His Pro Tyr Ser Tyr Gln Ser Pro
          210          215          220
Gly Leu Pro Ser Pro Pro Tyr Gly Thr Met Asp Ser Ser His Val Phe
          225          230          235          240
His Val Lys Pro Pro Pro His Ala Tyr Ser Ala Ala Leu Glu Pro Phe
          245          250          255
Phe Glu Ser Pro Leu Thr Asp Cys Thr Ser Pro Ser Phe Asp Gly Pro
          260          265          270
Leu Ser Pro Pro Leu Ser Ile Asn Gly Asn Phe Ser Phe Lys His Glu
          275          280          285
Pro Ser Ala Glu Phe Glu Lys Asn Tyr Ala Phe Thr Met His Tyr Pro
          290          295          300

```

Ala Ala Thr Leu Ala Gly Ala Gln Ser His Gly Ser Ile Phe Ser Gly
 305 310 315 320
 Thr Ala Ala Pro Arg Cys Glu Ile Pro Ile Asp Asn Ile Met Ser Phe
 325 330 335
 Asp Ser His Ser His His Glu Arg Val Met Ser Ala Gln Leu Asn Ala
 340 345 350
 Ile Phe His Asp
 355

<210> 9

<211> 382

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (0)...(0)

<223> Neurogenic basic helix-loop-helix protein (neuro
 D2); Genbank Accession U58681.

<400> 9

Met Leu Thr Arg Leu Phe Ser Glu Pro Gly Leu Leu Ser Asp Val Pro
 1 5 10 15
 Lys Phe Ala Ser Trp Gly Asp Gly Glu Asp Asp Glu Pro Arg Ser Asp
 20 25 30
 Lys Gly Asp Ala Pro Pro Pro Pro Pro Ala Pro Gly Pro Gly Ala
 35 40 45
 Pro Gly Pro Ala Arg Ala Ala Lys Pro Val Pro Leu Arg Gly Glu Glu
 50 55 60
 Gly Thr Glu Ala Thr Leu Ala Glu Val Lys Glu Glu Gly Glu Leu Gly
 65 70 75 80
 Gly Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Gly Leu Asp Glu Ala
 85 90 95
 Glu Gly Glu Arg Pro Lys Lys Arg Gly Pro Lys Lys Arg Lys Met Thr
 100 105 110
 Lys Ala Arg Leu Glu Arg Ser Lys Leu Arg Arg Gln Lys Ala Asn Ala
 115 120 125
 Arg Glu Arg Asn Arg Met His Asp Leu Asn Ala Ala Leu Asp Asn Leu
 130 135 140
 Arg Lys Val Val Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile
 145 150 155 160
 Glu Thr Leu Arg Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile
 165 170 175
 Leu Arg Ser Gly Lys Arg Pro Asp Leu Val Ser Tyr Val Gln Thr Leu
 180 185 190
 Cys Lys Gly Leu Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu
 195 200 205
 Gln Leu Asn Ser Arg Asn Phe Leu Thr Glu Gln Gly Ala Asp Gly Ala
 210 215 220
 Gly Arg Phe His Gly Ser Gly Gly Pro Phe Ala Met His Pro Tyr Pro
 225 230 235 240
 Tyr Pro Cys Ser Arg Leu Ala Gly Ala Gln Cys Gln Ala Ala Gly Gly
 245 250 255
 Leu Gly Gly Gly Ala Ala His Ala Leu Arg Thr His Gly Tyr Cys Ala

```

                260                265                270
Ala Tyr Glu Thr Leu Tyr Ala Ala Ala Gly Gly Gly Gly Ala Ser Pro
                275                280                285
Asp Tyr Asn Ser Ser Glu Tyr Glu Gly Pro Leu Ser Pro Pro Leu Cys
                290                295                300
Leu Asn Gly Asn Phe Ser Leu Lys Gln Asp Ser Ser Pro Asp His Glu
305                310                315                320
Lys Ser Tyr His Tyr Ser Met His Tyr Ser Ala Leu Pro Gly Ser Arg
                325                330                335
Pro Thr Gly His Gly Leu Val Phe Gly Ser Ser Ala Val Arg Gly Gly
                340                345                350
Val His Ser Glu Asn Leu Leu Ser Tyr Asp Met His Leu His His Asp
                355                360                365
Arg Gly Pro Met Tyr Glu Glu Leu Asn Ala Phe Phe His Asn
370                375                380

```

```

<210> 10
<211> 238
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> PEPTIDE
<222> (0)...(0)
<223> Achaete scute homologous protein (ASH1); Genbank
        Accession L08424.

```

```

<400> 10
Met Glu Ser Ser Ala Lys Met Glu Ser Gly Gly Ala Gly Gln Gln Pro
 1                5                10                15
Gln Pro Gln Pro Gln Gln Pro Phe Leu Pro Pro Ala Ala Cys Phe Phe
                20                25                30
Ala Thr Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Gln
                35                40                45
Ser Ala Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
 50                55                60
Ala Pro Gln Leu Arg Pro Ala Ala Asp Gly Gln Pro Ser Gly Gly Gly
65                70                75                80
His Lys Ser Ala Pro Lys Gln Val Lys Arg Gln Arg Ser Ser Ser Pro
                85                90                95
Glu Leu Met Arg Cys Lys Arg Arg Leu Asn Phe Ser Gly Phe Gly Tyr
                100                105                110
Ser Leu Pro Gln Gln Gln Pro Ala Ala Val Ala Arg Arg Asn Glu Arg
                115                120                125
Glu Arg Asn Arg Val Lys Leu Val Asn Leu Gly Phe Ala Thr Leu Arg
130                135                140
Glu His Val Pro Asn Gly Ala Ala Asn Lys Lys Met Ser Lys Val Glu
145                150                155                160
Thr Leu Arg Ser Ala Val Glu Tyr Ile Arg Ala Leu Gln Gln Leu Leu
                165                170                175
Asp Glu His Asp Ala Val Ser Ala Ala Phe Gln Ala Gly Val Leu Ser
                180                185                190
Pro Thr Ile Ser Pro Asn Tyr Ser Asn Asp Leu Asn Ser Met Ala Gly
195                200                205

```



```

Ser Pro Val Ser Ser Tyr Ser Ser Asp Glu Gly Ser Tyr Asp Pro Leu
 210                215                220
Ser Pro Glu Glu Gln Glu Leu Leu Asp Phe Thr Asn Trp Phe
 225                230                235

```

```

<210> 11
<211> 447
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> PEPTIDE
<222> (0)...(0)
<223> Zic 1 protein; Genbank Accession D76435.

```

```

<400> 11
Met Leu Leu Asp Ala Gly Pro Gln Tyr Pro Ala Ile Gly Val Thr Thr
 1                5                10                15
Phe Gly Ala Ser Arg His His Ser Ala Gly Asp Val Ala Glu Arg Asp
 20                25                30
Val Gly Leu Gly Ile Asn Pro Phe Ala Asp Gly Met Gly Ala Phe Lys
 35                40                45
Leu Asn Pro Ser Ser His Glu Leu Ala Ser Ala Gly Gln Thr Ala Phe
 50                55                60
Thr Ser Gln Ala Pro Gly Tyr Ala Ala Ala Ala Leu Gly His His
 65                70                75                80
His His Pro Gly His Val Gly Ser Tyr Ser Ser Ala Ala Phe Asn Ser
 85                90                95
Thr Arg Asp Phe Leu Phe Arg Asn Arg Gly Phe Gly Asp Ala Ala Ala
 100               105               110
Ala Ala Ser Ala Gln His Ser Leu Phe Ala Ala Ser Ala Gly Gly Phe
 115               120               125
Gly Gly Pro His Gly His Thr Asp Ala Ala Gly His Leu Leu Phe Pro
 130               135               140
Gly Leu His Glu Gln Ala Ala Gly His Ala Ser Pro Asn Val Val Asn
 145               150               155               160
Gly Gln Met Arg Leu Gly Phe Ser Gly Asp Met Tyr Pro Arg Pro Glu
 165               170               175
Gln Tyr Gly Gln Val Thr Ser Pro Arg Ser Glu His Tyr Ala Ala Pro
 180               185               190
Gln Leu His Gly Tyr Gly Pro Met Asn Val Asn Met Ala Ala His His
 195               200               205
Gly Ala Gly Ala Phe Phe Arg Tyr Met Arg Gln Pro Ile Lys Gln Glu
 210               215               220
Leu Ile Cys Lys Trp Ile Glu Pro Glu Gln Leu Ala Asn Pro Lys Lys
 225               230               235               240
Ser Cys Asn Lys Thr Phe Ser Thr Met His Glu Leu Val Thr His Val
 245               250               255
Thr Val Glu His Val Gly Gly Pro Glu Gln Ser Asn His Ile Cys Phe
 260               265               270
Trp Glu Glu Cys Pro Arg Glu Gly Lys Pro Phe Lys Ala Lys Tyr Lys
 275               280               285
Leu Val Asn His Ile Arg Val His Thr Gly Glu Lys Pro Phe Pro Cys
 290               295               300

```

```

Pro Phe Pro Gly Cys Gly Lys Val Phe Ala Arg Ser Glu Asn Leu Lys
305                      310                      315                      320
Ile His Lys Arg Thr His Thr Gly Glu Lys Pro Phe Lys Cys Glu Phe
                      325                      330                      335
Glu Gly Cys Asp Arg Arg Phe Ala Asn Ser Ser Asp Arg Lys Lys His
                      340                      345                      350
Met His Val His Thr Ser Asp Lys Pro Tyr Leu Cys Lys Met Cys Asp
                      355                      360                      365
Lys Ser Tyr Thr His Pro Ser Ser Val Arg Lys His Met Lys Val His
                      370                      375                      380
Glu Ser Ser Ser Gln Gly Ser Gln Pro Ser Pro Ala Ala Ser Ser Gly
385                      390                      395                      400
Tyr Glu Ser Ser Thr Pro Pro Thr Ile Val Ser Pro Ser Thr Asp Asn
                      405                      410                      415
Pro Thr Thr Ser Ser Leu Ser Pro Ser Ser Ser Ala Val His His Thr
                      420                      425                      430
Ala Gly His Ser Ala Leu Ser Ser Asn Phe Asn Glu Trp Tyr Val
                      435                      440                      445

```

<210> 12
 <211> 725
 <212> PRT
 <213> Homo sapiens

<220>
 <221> PEPTIDE
 <222> (0)...(0)
 <223> Myelin transcription factor 1 (My T1); Genbank
 Accession M96980.

```

<400> 12
Arg Lys Ser Tyr Tyr Ser Lys Asp Pro Ser Arg Ala Glu Lys Arg Glu
1                      5                      10                      15
Ile Lys Cys Pro Thr Pro Gly Cys Asp Gly Thr Gly His Val Thr Gly
                      20                      25                      30
Leu Tyr Pro His His Arg Ser Leu Ser Gly Cys Pro His Lys Asp Arg
                      35                      40                      45
Ile Pro Pro Glu Ile Leu Ala Met His Glu Asn Val Leu Lys Cys Pro
50                      55                      60
Thr Pro Gly Cys Thr Gly Gln Gly His Val Asn Ser Asn Arg Asn Thr
65                      70                      75                      80
His Arg Ser Leu Ser Gly Cys Pro Ile Ala Ala Glu Lys Leu Ala
                      85                      90                      95
Lys Ser His Glu Lys Gln Gln Pro Gln Thr Gly Asp Pro Ser Lys Ser
                      100                      105                      110
Ser Ser Asn Ser Asp Arg Ile Leu Arg Pro Met Cys Phe Val Lys Gln
                      115                      120                      125
Leu Glu Val Pro Pro Tyr Gly Ser Tyr Arg Pro Asn Val Ala Pro Arg
130                      135                      140
His Thr Gln Gly Gln Leu Gly Lys Glu Leu Glu Lys Phe Ser Lys Val
145                      150                      155                      160
Thr Phe Asp Tyr Ala Ser Phe Asp Ala Gln Val Phe Gly Lys Arg Met
                      165                      170                      175
Leu Ala Pro Lys Ile Gln Thr Ser Glu Thr Ser Pro Lys Ala Phe Gln

```

```

      180      185      190
Ser Lys Pro Phe Pro Lys Ala Ser Ser Pro Arg His Ser Pro Ser Ser
      195      200      205
Ser Tyr Val Arg Ser Thr Ser Ser Ser Ala Gly Phe Asp Tyr Ser
      210      215      220
Gln Asp Ala Glu Ala Ala His Met Ala Ala Thr Ala Ile Leu Asn Leu
      225      230      235      240
Ser Thr Arg Cys Trp Glu Met Pro Glu Asn Leu Ser Thr Lys Pro Gln
      245      250      255
Asp Leu Pro Ser Lys Ser Val Asp Ile Glu Val Asp Glu Asn Gly Thr
      260      265      270
Leu Asp Leu Ser Met His Lys His Arg Lys Arg Glu Asn Ala Phe Pro
      275      280      285
Ser Ser Ser Ser Cys Ser Ser Ser Pro Gly Val Lys Ser Pro Asp Ala
      290      295      300
Ser Gln Arg His Ser Ser Thr Ser Ala Pro Ser Ser Ser Met Thr Ser
      305      310      315      320
Pro Gln Ser Ser Gln Ala Ser Arg Gln Asp Glu Trp Asp Arg Pro Leu
      325      330      335
Asp Tyr Thr Lys Pro Ser Arg Leu Arg Glu Glu Glu Pro Glu Glu Ser
      340      345      350
Glu Pro Ala Ala His Ser Phe Ala Ser Ser Glu Ala Asp Asp Gln Glu
      355      360      365
Val Ser Glu Glu Asn Phe Glu Glu Arg Lys Tyr Pro Gly Glu Val Thr
      370      375      380
Leu Thr Asn Phe Lys Leu Lys Phe Leu Ser Lys Asp Ile Lys Lys Glu
      385      390      395      400
Leu Leu Thr Cys Pro Thr Pro Gly Cys Asp Gly Ser Gly His Ile Thr
      405      410      415
Gly Asn Tyr Ala Ser His Arg Ser Leu Ser Gly Cys Pro Leu Ala Asp
      420      425      430
Lys Ser Leu Arg Asn Leu Met Ala Thr His Ser Ala Asp Leu Lys Cys
      435      440      445
Pro Thr Pro Gly Cys Asp Gly Ser Gly His Ile Thr Gly Asn Tyr Ala
      450      455      460
Ser His Arg Ser Leu Ser Gly Cys Pro Arg Ala Lys Lys Ser Gly Val
      465      470      475      480
Lys Val Ala Pro Thr Lys Asp Asp Lys Glu Asp Pro Glu Leu Met Lys
      485      490      495
Cys Pro Val Pro Gly Cys Val Gly Leu Gly His Ile Ser Gly Lys Tyr
      500      505      510
Ala Ser His Arg Ser Ala Ser Gly Cys Pro Leu Ala Ala Arg Arg Gln
      515      520      525
Lys Glu Gly Ser Leu Asn Gly Ser Ser Phe Ser Trp Lys Ser Leu Lys
      530      535      540
Asn Glu Asp Pro Thr Cys Pro Thr Pro Gly Cys Asp Gly Ser Gly His
      545      550      555      560
Thr Ile Gly Ser Phe Leu Thr His Arg Ser Leu Ser Gly Cys Pro Arg
      565      570      575
Ala Thr Phe Ala Gly Lys Lys Gly Lys Leu Ser Gly Asp Glu Val Leu
      580      585      590
Ser Pro Lys Phe Lys Thr Ser Asp Val Leu Glu Asn Asp Glu Glu Ile
      595      600      605
Lys Gln Leu Asn Gln Glu Ile Arg Asp Leu Asn Glu Ser Asn Ser Glu

```

```

      610              615              620
Met Glu Ala Ala Met Val Gln Leu Gln Ser Gln Ile Ser Ser Met Glu
625              630              635              640
Lys Asn Leu Lys Asn Ile Glu Glu Glu Asn Lys Leu Ile Glu Glu Gln
      645              650              655
Asn Glu Ala Leu Phe Leu Glu Leu Ser Gly Leu Ser Gln Ala Leu Ile
      660              665              670
Gln Ser Leu Ala Asn Ile His Leu Pro His Met Glu Pro Ile Cys Glu
      675              680              685
Gln Asn Phe Val Pro Tyr Val Ser Thr Leu Thr Asp Met Tyr Ser Asn
      690              695              700
Gln Ala Pro Glu Asn Lys Asp Leu Leu Glu Ser Ile Lys Gln Ala Val
705              710              715              720
Arg Gly Ile Gln Val
      725

```

```

<210> 13
<211> 27
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> gene
<222> (0)...(0)
<223> MSX1 antisense oligonucleotide sequence MSX1-1

```

```

<400> 13
gacaccgagt ggcaaagaag tcatgtc

```

27

```

<210> 14
<211> 24
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> gene
<222> (0)...(0)
<223> MSX1 antisense oligonucleotide sequence MSX1-2

```

```

<400> 14
cggcttctctg tggtcggcca tgag

```

24

```

<210> 15
<211> 35
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> gene
<222> (0)...(0)
<223> HES1 open reading frame 5' sequence (HES1-1)

```

```

<400> 15
accgggggacg aggaattttt ctccattata tcagc

```

35

<210> 16
<211> 40
<212> DNA
<213> Homo sapiens

<220>
<221> gene
<222> (0)...(0)
<223> HES1 open reading frame middle sequence (HES1-2)

<400> 16
cacggagggtg ccgctgttgc tgggctggtg tggtagtagac

40

20. Jan. 2000

ABSTRACT

Disclosed is a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological features of a neural progenitor, neuronal, or glial cell by culturing a proliferating epidermal basal cell population
5 derived from the skin of a mammalian subject; transfecting the cells, in vitro, with one or more eukaryotic expression vector(s) that contain at least one cDNA encoding a human neurogenic transcription factor, or homologous non-human counterpart, or active fragment(s) thereof, such as NeuroD1, NeuroD2, ASH1, Zic1, Zic3, or MyT1, such that at least one of the neurogenic transcription factor(s) is expressed in the cell; growing the cells in an in vitro
10 growth medium in which is present at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and/or human HES1 gene, or homologous non-human counterpart of either of these, thereby suppressing at least one negative regulator of neuronal differentiation; and the cell(s) are, optionally, further grown with a retinoid and at least one neurotrophin, such as BDNF, CNTF, PDGF, NGF, NT-3, NT-4, or sonic hedgehog, or a
15 cytokine comprising IL-6. Also disclosed is a transdifferentiated cell of epidermal origin and cell cultures derived therefrom. In addition, methods of using the inventive transdifferentiated cell(s) and cell cultures to identify a novel nerve growth factor or to screen a potential chemotherapeutic agent by detecting the presence or absence of an effect, in vitro, on a morphological, physiological and/or molecular biological property of the
20 transdifferentiated cell(s) are described, as is a method of using the transdifferentiated cell(s) and cell cultures to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin. A kit useful for practicing the methods is disclosed.

13897.1

